research for
man and environment

RIJKSINSTITUUT VOOR VOLKSGEZONDHEID EN MILIEU
NATIONAL INSTITUTE OF PUBLIC HEALTH AND THE ENVIRONMENT

RIVM report 105000 001

A randomised controlled study with whole-cell or acellular pertussis vaccines in combination with regular DT-IPV vaccine and a new poliomyelitis (IPV-Vero) component in children 4 years of age in the Netherlands

G.A.M. Berbers, A.B. Lafeber,
J. Labadie, P.E. Vermeer-de Bondt,
D.J.A. Bolscher, A.D. Plantinga January 1999

This investigation has been performed by order and for the account of Chief Inspectorate of Health Care, within the framework of project 105030, clinical trials new RIVM vaccines.

RIVM, P.O. Box 1, 3720 BA Bilthoven, telephone: 31 - 30 - 274 91 11; telefax: 31 - 30 - 274 29 71

Abstract

In this trial we have studied the immunogenicity and reactogenicity of 3 different acellular pertussis vacccines and the whole cell vaccine from the RIVM combined with DT-IPV administered as a booster in children 4 years of age. In these children, the immune response of IPVvero (produced on Vero cells) was also evaluated together with the regular IPV-MK (produced on monkey kidney cells). The children in this study were immunized 3 years earlier with 4 doses of the RIVM DTP-IPV at the age of 3, 4, 5 and 11 months. The acellular vaccines were composed of PT and FHA (2 component vaccine from Pasteur Merieux), PT, FHA and PRN (3 component vaccine from Smithkline Biologicals) and PT, FHA, PRN and FIM (4 component vaccine from Wyeth Lederle/Takeda). The study was an open, randomised, controlled study with a blinded serological evaluation. All the responses to the different vaccine components clearly demonstrate that the children are well primed with the DTP-IPV.
In conclusion, this study demonstrates that an addition of a pertussis vaccination in 4 year old children might be useful in an epidemical situation, in which a combination vaccine (with acellular or whole cell pertussis component) is to be preferred because of the single administration. Furthermore, the IPVvero shows to be a very immunogenic vaccine and the response is at least the same as observed for the regular IPV-MK.

Acknowledgements

We wish to thank for their participation in this study:

Stichting Thuiszorg Oost-Veluwe:
G.M. Bolscher-Heijmen, A.J. Bouma, S.S. van Dinten, E. Naarding,
G. Roussel-Diederik, K. Stegeman, J. Trumpi, B. de Widt, E.J. Wieland

Stichting Provinciale Entadministratie Gelderland:
C. Verhaaff

RIVM:
LVO: Laboratory for Clinical Vaccine Research
Pieter van Gageldonk, Karen Knipping, Kees van Limpt, Ton Marzec (PT, FHA, PRN and agglutination assays, D- en T-ToBI assays)
Monique Maas (MIRAI) - monitor
Deborah Kleijne, Irene Korting, Hans Rümke

LCB: Laboratory of Control of Biologics
Tanja Antonioli, Nasrin Elzinga-Gholizadea, Dick Jut (polio neutralisation assays)

LIS: Diagnostic Laboratory for Infectious Diseases and Perinatal Screening
Hans Boshuis, Bert Elvers (IgA whole cell assay)

IMA: Computarization and Methodological Consultancy
Nico Nagelkerke

Klinik für Kinder und Jugendliche der Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany:
Imke Bartels (fimbriae ELISA)

Wyeth-Lederle Vaccines:
Norbert Ahlers

For critically reading the manuschript:

Coen Beuvery, Frits Mooi, Hans Rümke and Joop Schellekens

Abbreviations

ACV	Acellular Vaccine
°C	Degrees Centigrade
CB	Child Health Clinic *(consultatiebureau)*
$CCID_{50}$	Cell Culture Infectious Dose
CI	Confidence Interval
CRF	Case Report Form
D-ag	poliovirus D-antigen units
DT-IPV	Diphtheria, Tetanus and Inactivated Poliovirus Vaccine *(Difterie, Tetanus, Polio (DTP) vaccin)*
DTP-IPV	Diphtheria, Tetanus, Pertussis (-whole cell) and Inactivated Poliovirus Vaccine *(Difterie, Kinkhoest, Tetanus, Polio (DKTP) vaccin)*
ELISA	Enzyme Linked Immuno Sorbent Assay
EU	ELISA units
FHA	Filamentous Hemagglutinin
FIM	Fimbriae
GCP	Good Clinical Practice
GMT	geometric mean titer
IgA	Immunoglobulin A
IgA-WC	IgA Whole Cell ELISA
IgG	Immunoglobulin G
IU	International Units
IOU	International Opacity Units
IPV-MK	Inactivated Polio Vaccine grown on monkey kidney cells
IPVv	Inactivated Polio Vaccine grown on Vero cells
IPVvero	Inactivated Polio Vaccine grown on Vero cells
kD	kiloDalton
KRZ	Bureau for Quality and Regulatory Affairs *(Bureau Kwaliteits en Registratiezaken RIVM)*
LCB	Laboratory for Control of Biological products *(Laboratorium voor Controle Biologische Produkten)*
LIO	Laboratory for Research of Infectious Diseases *(Laboratorium voor Infectieziektenonderzoek)*
LIS	Diagnostic Laboratory for Infectious Diseases and Perinatal Screening *(Laboratorium voor Infectieziektendiagnostiek en Screening)*
Lf	Flocculation units *(Limes flocculationes)*
Ln	Natural Logarithm
LPO	Laboratory for Product and Process Development *(Laboratorium voor Produkt- en Procesontwikkeling)*
LVO	Laboratory for Clinical Vaccine Research *(Laboratorium voor Veldonderzoek vaccins)*
LVO-BI	LVO Bio- and Immunochemistry section *(LVO afdeling bio- en immunochemie)*
MLD	Minimum Level of Detection
OR	Odds ratio

PEA	Immunisation Administration *(Provinciale Entadministratie)*
PM	Pasteur Merieux MSD
PRN	Pertactin
PT	Pertussis Toxin
RIVM	National Institute of Public Health and the Environment *(Rijksinstituut voor Volksgezondheid en Milieu)*
RVP	National Childhood Immunisation Programme *(Rijksvaccinatieprogamma)*
SB	Smithkline Biologicals
SDS	Sodium Dodecyl Sulphate
SOP	Standard Operating Procedure
SVM	Foundation for the Advancement of Public Health *(Stichting Bevordering Volksgezondheid en Milieu)*
ToBI	Toxin Binding Inhibition assay
UTN	Unique Trial Number
WCV	Whole cell vaccine
WHO	World Health Organization
WL	Wyeth Lederle /Takeda

Contents

Samenvatting

Doel/Opzet
In deze studie hebben we de immunogeniciteit en de reactogeniciteit van 3 verschillende ACV's en WCV van het RIVM onderzocht, gecombineerd met DTP toegediend als booster bij 4-jarige kinderen. Bij deze kinderen is tevens de immuunrespons op IPVvero (geproduceerd op Vero cellen) vergeleken met het reguliere IPV-MK (geproduceerd op MK cellen). De kinderen in deze studie zijn eerder gevaccineerd met 4 doses DKTP van het RIVM op de leeftijd van 3, 4, 5 en 11 maanden. De ACV's bevatten PT en FHA (ACV-PM), met PRN als derde component (ACV-SB) en FIM als vierde component (AVC-WL). Het was een open, gerandomiseerde, gecontroleerde studie met geblindeerde serologische bepalingen.

Resultaten en conclusies

De immuunrespons tegen de verschillende vaccincomponenten geeft duidelijk aan dat de kinderen in hun eerste levensjaar goed geprimed zijn met het WCV als component van DKTP van het RIVM. De GMT's tegen de pertussis antigenen, zoals in deze studie bepaald, komen goed overeen met de titers in internationale veldonderzoeken met deze ACV's.

ACV
Alle drie de ACV's induceren een uitstekende respons tegen de pertussis componenten, in zoverre deze antigenen deel uitmaken van de vaccins. Alhoewel de hoeveelheid PT in het ACV-WL 8 maal lager is dan in de andere twee ACV's, is de respons toch gelijk tot 2 maal hoger, hetgeen kan wijzen op verschillende detoxificatie procedures van PT. De immuunrespons tegen Aggl. en FIM in de ACV-PM groep duidt erop dat er waarschijnlijk toch een kleine hoeveelheid FIM in dit vaccin zit.

WCV
De WCV groepen vertonen een zeer brede immuunrespons, waarbij vooral de respons tegen Aggl. en FIM opviel en zelfs beter was dan voor het ACV-WL. De respons tegen FHA en PRN was voldoende, maar tegen PT wat aan de lage kant. De absolute titers tegen PT, FHA en PRN zijn beduidend lager dan die gemeten bij de ACV's, hetgeen toe te schrijven is aan de lagere hoeveelheid van deze antigenen in het WCV van het RIVM. In het merendeel van de kinderen van de WCV groepen werd een onverwachte IgA-respons gemeten, waarvan de biologische relevantie nog vastgesteld dient te worden.

Bijwerkingen
Er vonden geen ernstige bijwerkingen plaats in deze studie. Zoals verwacht veroorzaakte de toediening van het WCV meer algemene en lokale bijwerkingen dan de ACV's, maar er was slechts sprake van mild tot matig ongemak vooral beperkt tot de eerste dag na vaccinatie. De frequentie van de milde bijwerkingen was gunstig vergeleken met die gevonden bij baby's en lijkt hogere reactogeniteit van het WCV bij oudere kinderen niet te bevestigen.

IPV
Beide IPV-vaccins werkten uitstekend in deze studie. Het viervoudige verschil in de hoeveelheid antigeen van polio type 3 in de twee vaccins kan de oorzaak zijn van het significante verschil in respons, dat overigens waarschijnlijk niet klinisch relevant is gezien de extreem hoge titers. Er was geen verschil in bijwerkingen tussen het IPVvero en IPV-MK.

D en T
De immuunrespons tegen het Difterie toxoïd en het Tetanus toxoïd was ook zeer goed. In de DKTP groepen bleek de respons tegen Difterie toxoïd significant hoger te zijn dan in de andere vaccin groepen, hetgeen verklaard kan worden door de grotere hoeveelheid toxoïd in dit vaccin en het adjuverende effect van de WCV-component.

Samenvattend geeft deze studie aan dat een toevoeging van een pertussis vaccinatie op 4-jarige leeftijd zinvol kan zijn bij een epidemische verheffing, waarbij de voorkeur uitgaat naar een combinatievaccin met een ACV- of een WCV-component vanwege de enkelvoudige toediening. Het IPVvero blijkt een zeer immunogeen vaccin te zijn en op zijn minst gelijkwaardig aan het huidige IPV-MK.

Summary

Aim/Design
In this trial we have studied the immunogenicity and reactogenicity of 3 different ACV's and the RIVM-WCV combined with DT-IPV administered as a booster in children 4 years of age. In these children, the immune response of IPVvero (produced on Vero cells) was also evaluated together with the regular IPV-MK (produced on MK cells). The children in this study were previously immunized with 4 doses of the RIVM DTP-IPV at the age of 3, 4, 5 and 11 months. The ACV's were composed of PT and FHA (ACV-PM), with PRN as 3rd component (ACV-SB) and FIM as 4th component (ACV-WL). The study was an open, randomised, controlled study with a blinded serological evaluation.

Results and conclusions

All the responses to the different vaccine components clearly demonstrate that the children are well primed with WCV as component of DTP-IPV. The GMT's of the pertussis antigens determined in this study are in agreement with the titers observed in other trials with these ACV's.

ACV
All three ACV's induce an excellent response to the pertussis components that are included in the vaccines. The near equal GMT-PT in the different ACV groups, despite the 8-fold lower PT content in ACV-WL may reflect different detoxification procedures of PT. The immune responses to Aggl. and FIM in the ACV-PM group indicate that a small amount of fimbriae is likely to be present in this vaccine.

WCV
The WCV groups showed a very broad immune response. Especially the response against Aggl. and FIM was very good and better than for ACV-WL, the response against FHA and PRN satisfactorily, but against PT somewhat low. The absolute titers to PT, FHA and PRN were considerably lower than observed for the ACV's reflecting the smaller amounts of these antigens present in the RIVM-WCV. Vaccination with DTP-IPV also evoked an unexpected IgA-response in the majority of the children. The biological relevance of this finding is still under investigation.

Adverse events
No serious adverse events occurred during the study. As expected the WCV recipients had more frequent systemic and local symptoms, but generally there was only mild to moderate discomfort, mainly limited to the first day after vaccination. Compared to studies in infants, the rate of adverse events in this group of four year olds is favourable and does not suggest higher reactogenicity of WCV in older children.

IPV
Both IPV-vaccines performed very well in this study. The significant difference in response to polio type 3 may reflect the fourfold difference in the antigen content of this type in the two vaccines, which is most probably of insignificant clinical relevance because of the extreme high antibody titers. No difference in adverse events was observed between the administration of IPV-MK and IPVvero.

D and T
The immune response to Diphtheria toxoid and Tetanus toxoid was also very good. In the DTP-IPV groups the immune response to Diphtheria toxoid was significantly larger than in the other vaccine groups due to the greater antigen content of toxoid in this vaccine and the adjuvant effect of the pertussis WCV-component.

In conclusion, this study demonstrates that an addition of a pertussis vaccination in 4 year old children might be advantageous in an epidemical situation, in which a combination vaccine with an ACV- or a WCV-component is to be preferred requiring a single administration. IPVvero shows to be a very immunogenic vaccine and at least similar to the regular IPV-MK.

1. Introduction

1.1 Whooping Cough

Whooping cough was one of the most frequent and severe diseases of infants in the first part of this century. It has a significant mortality rate in infants but in adults it is a relatively mild disease. The development and application of whole cell vaccines in the 1950s has made pertussis an uncommon disease in the developed countries (53).
The agent of whooping cough (pertussis), *Bordetella pertussis*, is a very small Gram-negative aerobic coccobacillus, that is not assigned to any family of bacteria but taxonomically placed among the "Gram-negative aerobic rods and cocci". Its metabolism is respiratory, never fermentative and the bacteria are usually cultivated on rich media supplemented with blood or synthetic medium supplemented with amino acid energy sources and growth factors such as nicotinamide. The bacterium is a pathogen for humans and possibly higher primates and no other reservoir is known.
In the Netherlands, a rise in notifications and higher incidence rates were observed every 3-5 years in the vaccine-era. The unexpected sharp rise in cases in 1996-1997 (48, 49) is the motive of the underlying study of a booster immunisation with acellular or whole cell pertussis vaccines in 4 year old children.

1.2 Pathogenesis

Whooping cough is a serious, highly contagious disease caused by the bacterium *Bordetella pertussis* and more rarely by *B. parapertussis*. Once *B. pertussis* has entered the host, attachment to cilia in the respiratory mucosa can follow through adhesins and/or bacterial surface attachment factors. When immunological constraints are absent, the organism will proliferate and spread downward in the respiratory tract. During this time several toxins are released, helping the bacteria to overcome defense systems of the host and causing the later severe clinical symptoms of the respiratory tract. These toxins can enter the bloodstream and thereby reach distant tissues, causing symptoms throughout the body. The incubation period is seven to ten days. The onset of the illness is subtle: undistinct upper respiratory tract infection mimicking a common cold with mild cough and sometimes low grade fever. This is the catarrhal stage. During the next stage of pertussis, the coughing becomes increasingly forceful and the typical coughing attacks occur. This is the paroxysmal stage. At the top of the illness patients may experience 10 or more paroxysms in 24 hours. Each paroxysm is likely to result in significant hypoxia, especially in young children. Generally this stage lasts from 1 to 4 weeks. After that the paroxysms become less severe and less frequent. The last stage of pertussis is called the convalescent stage. Patients are usually free of *B. pertussis* organisms before this stage despite persistent coughing.
In young infants, whooping cough is particularly severe with atypical presentation of the disease, and morbidity and mortality rates are high. In non-immunised older children and adults, the typical but milder disease with less complications is mostly seen. Once vaccinated, a more atypical mild disease is observed. Unless started in the catarrhal early stage, antibiotics have little impact on the disease, because they are only effective in eradicating the bacterium and have no effect on the already produced toxins causing the clinical symptoms. Therefore, efforts have been focused on prevention (42).

1.3 Vaccination

1.3.1 WCV

Immunisation using a vaccine composed of whole cells of killed *B. pertussis* bacteria was formally introduced in the RVP in 1957, but large scale vaccination against pertussis started in 1953. Nowadays, children are vaccinated at the age of 3, 4, 5 and 11 months with a tetravalent diphtheria, tetanus, pertussis, and inactivated polio virus vaccine. This combined DTP-IPV vaccine was introduced in 1962 and has been used to immunise 4- and 9-year old children in the RVP, but in 1965 its use was limited to immunisations in the first year of life (31). The DT-IPV combination vaccine has also been introduced in 1962 and is used from 1965 up till now for booster vaccinations at 4 and 9 years of age. Before this date (1962) separate DT and IPV vaccines were used. This RVP mass vaccination has markedly decreased the incidence of *B. pertussis* and the mortality rates caused by the disease. Although the whole cell pertussis vaccine is efficacious in preventing the disease it is associated with a high frequency of local and general adverse events.

1.3.2 ACV

As a result of efforts to identify those *B. pertussis* antigens that induce protection from pertussis, new “acellular” vaccines have been developed. These vaccines are composed of specific purified antigens. Four components of *B. pertussis* have been characterized sufficiently to be considered for inclusion in acellular pertussis vaccines: pertussis toxin (PT), filamentous hemagglutinin (FHA), fimbriae (FIM) and pertactin (PRN).

Pertussis toxin (PT) is a 105 kD protein composed of six subunits: S1, S2, S3, S4 (2x) and S5. Within this AB_5 toxin, the S1 subunit is the A component with ADP-ribosylating activity on a family of GTP-binding (G) proteins. The B component composed of 5 subunits (S2-S5) binds to specific carbohydrates on cell surfaces and directs the entry of the A component into the cytoplasm of mammalian cells. The A subunit prevents by its enzymatic activity the normal inhibition of eukaryotic adenylate cyclase thereby inducing a continuous conversion of ATP to cyclic AMP, which eventually results in the clinical symptoms of *B. pertussis* (83). The immune response against PT is believed to play a central role in clinical protection in humans. Recently, three S1 variants which show small differences in amino acid sequence, have been characterized using strains collected from Dutch patients (52).

Filamentous hemagglutinin (FHA) is a large protein (220kD) which is proteolytically processed from a much larger precursor. FHA forms filamentous, rod-like structures on the cell surface, loosely associated with the cell wall. FHA promotes adherance of *B. pertussis* through binding to galactose residues on a sulfated glycolipid which is very common on the surface of ciliated cells of the respiratory epithelium. FHA contains a tripeptide of arginine, glycine and aspartic acid (RGD), a consensus sequence by which integrins recognise receptors (83). Until recently, antibodies against FHA were believed to provide protection against infection (11, 32, 40, 67, 68).

Fimbriae (FIM) are surface structures that mediate adherence. They induce agglutinating antibodies, which have been correlated with immunity to pertussis after vaccination with whole-cell vaccines. Although pertussis contains at least 3 fimbrial genes (i.e. *fim 2*, *fim 3* and *fim x*) only *fim 2* and *fim 3* are known to be expressed by clinical isolates.

Pertactin (PRN) is an outer membrane protein of 69 kD, which is synthesized by proteolytic processing of a 93kD precursor. Like FHA, PRN contains the tripeptide RGD, the sequence motif through which it is involved in adherence to human host cells (83). Polymorphism has recently been established in PRN and is confined to a possibly immunogenic region comprised of repeats and located proximal to the RGD motif (52).

Acellular vaccines have been used for vaccination for several years in different countries, like Japan, Germany and the United States. Several studies have shown that acellular vaccines cause fewer and milder local and general adverse events than whole cell vaccines. Serological correlates of pertussis immunity are not defined, but it is proven that most acellular vaccines can induce comparable or higher serum antibody responses than whole cell pertussis vaccines for those antigens contained in the vaccines (12, 19, 36). The acellular pertussis vaccines have been extensively studied as single vaccine and combined with other vaccines. These vaccines are registered in several countries, but not in the Netherlands. They were never studied in combination with RIVM DT-IPV(v) vaccines.

1.4 P-vero

Inactivated poliovirus vaccine (IPV) has a long standing record of safety and high efficacy (74,75). Its immunogenicity correlates well with excellent individual protection against poliomyelitis, as shown in several European countries, including the Netherlands and Scandinavian countries. Endemic poliomyelitis disappeared after introduction of trivalent IPV in national immunization programmes (9, 57, 58, 71, 72). Also in developing countries the protective efficacy has been proven (69, 73, 77, 78). In the Netherlands, the two most recent epidemics (in 1978 and 1992-93) occurred in specific religious communities, and are attributed to failure to vaccinate and not to vaccine failure (57, 58).

A major factor limiting large scale production of IPV is the source of suitable cells for virus propagation. Up till now, the RIVM has used monkey kidney cells. At present, 15 - 20 monkeys each year have to be sacrificed for regular IPV production, for national use as well as export. Therefore, alternative cell sources have been investigated in which poliovirus can be propagated effectively at a large scale. The use of Vero cells for this purpose is a reliable alternative and less expensive, with the following other advantages over the currently used monkey kidney cells:

- The Vero cell is a cell line, which makes further use of animals for virus propagation unnecessary.
- Vero cells are better standardised than monkey kidney cells.
- Vero cells have a smaller risk of being contaminated than the monkeys and their kidney cells.

Vero cells are derived from monkey kidney cells. The Vero cells are widely used for production of vaccines (IPV and rabies virus vaccine). Such vaccines are considered safe and potent. The American Food and Drug Administration has licensed an IPV based on Vero cells for unrestricted use in the United States.

The RIVM initiated clinical studies with IPV derived from polioviruses grown in Vero cells, further termed IPV-Vero. The virus strains used for this new vaccine are the same as for the vaccine in present use, the Salk virus Mahoney (type 1), MEF-1 (type 2) and Saukett (type 3) strains. The vaccine is immunochemically and biochemically equivalent to the IPV-MK. The only difference is the cell substrate for virus propagation. In a phase I/II study in adults safety

and excellent booster immunogenicity were demonstrated (50, 70). In Norway a phase II study in babies is in progress.

1.5 Aim of the study

Pertussis is an illness with a classical epidemic cycle of 3 to 5 years, even after the introduction of pertussis vaccination. This suggests that vaccination is effective in controlling the disease but not in decreasing the circulation of the organism in the population. The unexpected high number of pertussis cases in 1996-'97 (48, 49) was the motive for this study. The aim of the study was to assess the immune response against pertussis vaccine components in four year old children after booster immunisations with whole cell and acellular pertussis vaccines both in combination with the regular DT-IPV vaccine (60). The reactogenicity of the different pertussis vaccines was compared. Furthermore, the immune response against the new poliomyelitis vaccine grown on Vero cells was assessed in comparison with the regular IPV-MK. These children were primed with 4 doses of RIVM DTP-IPV (containing whole cell pertussis and inactivated polio vaccine grown in monkey kidney cells) in the first year of life.

2. Materials and methods

2.1 Vaccines

The composition of the different vaccines used in the study is given in Table 1. The following vaccine combinations (lotnumbers between brackets) were studied:

1. DT-IPV as control group (108A)
2. DTP-IPV (184A)
3. DT-IPVv (70373A)
4. DTP-IPVv (70374A)
5. DT-IPV + ACV-SB (108A + 19002B2)
6. DT-IPVv + ACV-SB (70373A + 19002B2)
7. DT-IPV + ACV-WL (108A + 97F04D)
8. DT-IPV + ACV-PM (108A + S3515)

Vaccines were stored in Apeldoorn at a central CB under standard conditions (dedicated vaccines/medicines refrigerator; temperature at 2-8° C; continuous temperature monitoring with auto-dial telephone alert; secured power supply). Adequate packaging under supervision of SVM assured exclusive use of vaccines with lotnumbers assigned for this study. The vaccinations were registered on cards (“blauwe randkaarten”) for the PEA to be entered in the central vaccination record of the child.

Table 1. The composition of the acellular and whole cell pertussis vaccines and the regular DT-IPV and DTP-IPV per dose. The pertussis components are expressed in µg, the whole cell vaccine in IOU, diphtheria toxoid (DT) and tetanus toxoid (TT) in Lf and the polio strains (type 1, 2 and 3) in D-antigen units.

ACV/WCV	PT	FHA	PRN	FIM
Wyeth Lederle/Takeda (ACV-WL)	3.2	34.4	1.6	0.8
Smithkline Biologicals (ACV-SB)	25	25	8	-
Pasteur Merieux (ACV-PM)	25	25	-	-
RIVM-WCV	0.25	5.3	?	?

RIVM vaccines	Pertussis	DT	TT	P1	P2	P3
DTP-IPVv	16	15.0	5.0	42	8	32
DTP-IPV	16	15.0	5.0	38	4	8
DT-IPVv	-	2.5	5.0	42	7	43
DT-IPV	-	2.5	5.0	37	4	7

2.2 Participants

Children having their 4th birthday in 1998, living in the area where preventive child health care is provided by the Stichting Thuiszorg Oost-Veluwe, were invited to participate in the study by direct mailing from the PEA. Additional information was given to the parents, both in writing (in Dutch and in Arabic & Turkish) as well as orally and parent's questions were addressed. The catchment population was 2068 infants in the cities of Apeldoorn (5 CBs), Epe (1 CB) , Vaassen (1 CB) and Twello (1 CB).
After evaluation of inclusion and exclusion criteria and signing of the informed consent form by the parents, the child was enrolled: the assignment of the child using an in advance generated list, by Unique Trial Number to one of the 8 study groups, was at random. UTN's were assigned in order of enrolment. 32-unit blocks were used to ensure balanced assignment of the children to the 8 groups. This procedure and the block size were not revealed to the study personnel in the clinics.

2.3 Study design

The study was an open randomised controlled study in four year old children with blinded serological evaluation. The vaccines from the different manufacturers could not be blinded because they were supplied in their original packages, with the lotnumbers as a further identifier. Thus both parents and study personnel knew which specific vaccine the child received. Parents were informed about possible adverse events. The first blood sample was taken just prior to the vaccination. The second sampling was scheduled after 4-6 weeks. After vaccination the child remained under direct observation for about fifteen minutes. Any observed adverse events were recorded in a special diary for the seven days following the vaccination by the parents. The observed adverse events were (to be) put on the CRF by the study personnel during the telephone interview 18-30 hours after the vaccination and at the time of the second blood sampling.
Children of the groups not receiving one of the pertussis vaccines were offered either ACV-SB or ACV-WL vaccine, since a single WCV is not available. This was not part of the study and was recommended by the medical ethics committee.

2.4 Vaccination and blood sampling

A physician or a study nurse administered intramuscular injections according to standard procedures (12N-GCP-04 and 12N-GCP-05). DTP-IPV or DT-IPV were to be injected in the left upper arm and the acellular vaccines in the right upper arm. No instruction was given about skin desinfection. The lotnumber and injection site was registered in the CRF. Blood (5-10 ml) was sampled by venapuncture after application of a local anaesthetic (EMLA™). In a subset of the population a heparinized blood sample was also taken. The routing of the blood samples is described in detail in SOP 12N-ALG-04. After transportation to the RIVM at the end of the day serum was separated (SOP 12C-ALG-15) and stored at -20 ^{o}C until testing. The heparinized blood samples were handed over to LIO for blood cell isolation. These samples were taken to study the influence of the vaccinations on cellular immunity, in particular T-cell proliferation. The results of this part of the study will be reported later.

2.5 Immunogenicity

After all serum samples were collected they were thawed and randomized for blinded antibody measurement. Aliquots were divided into marked tubes with a Multiprobe (Canberra Packard, US) (SOP 12N-APP-34). To perform the 11 assays 6 portions were distributed to the participating labs in the following priority order (in case a limited amount of sample would be available):

1. Pertussis	PT-, FHA-, PRN- ELISA	LVO
2. Pertussis	Agglutination assay	LVO
3. Poliomyelitis	Neutralisation assay (3 strains)	LCB
4. Pertussis	FIM2-ELISA	Erlangen, Germany
5. Pertussis	IgA-whole cell ELISA	LIS
6. Diphtheria	Toxin Inhibition Binding assay (ToBI)	LVO
6. Tetanus	Toxin Inhibition Binding assay (ToBI)	LVO

2.5.1 Pertussis anti-PT, anti-FHA, anti-PRN and anti-FIM2 antibodies

ELISA's were performed according to SOP 12C-ALG-36 which is essentially the same procedure as described by Edwards en Meade et al (18, 46). Purified PT (S1-B variant) and FHA-proteins were provided by LPO (RIVM, The Netherlands) and PRN (variant 1) was purchased from CHIRON (Siena, Italy). Their purity was confirmed by SDS-gel electrophoresis. The coat concentration for PT was 1 μg/ml, for FHA 2 μg/ml and 3 μg/ml for PRN. For each serum, 8 twofold dilutions were tested starting with 1: 60 dilution. Alkaline phosphatase conjugated goat antihuman IgG (Sigma, St. Louis, US) was used at a dilution of 1: 30,000. The incubation time in all steps during the assay was 2 hours at 28^{o}C. ELISA unitage was calculated relative to the US Reference Pertussis Antiserum (human), lot 3 for PT and FHA and lot 4 for PRN using the four parameter fit method in KC4 (Kineticalc for Windows) with a BioTek plate reader (EL312e, BioTek Instruments, US) (SOP 12N-APP-50). The results from each plate were accepted if the reference revealed the original amount EU/ml in the linear part of the dose-response curve $\pm$ 10%, the slope of the curve had a $r \geq 0.995$ and the control serum was within its predetermined 95% confidence interval (mean $\pm$ 2 SD range). The coefficient of variation of the control sera within the whole study (inter-assay variation) was less than 20% for PT, FHA and PRN. The minimum level of detection (MLD) was defined as the minimum amount of antibody present for a serum to have at least one point in the linear part of the reference curve, and was estimated 2 EU/ml for PT and FHA and 4 EU/ml for PRN. For statistical calculations, sera with an unitage below the MLD were assigned a value equal to the half of the MLD, except for PRN 3 EU/ml.

The FIM2 antibodies were determined by Dr. Bartels in Erlangen according to the method described by Meade et al (46). Results were standardized by use of the US Pertussis Antiserum (human) lot 3 and the MLD was 1 EU/ml. Samples below the MLD were assigned the value 0.5 EU/ml.

2.5.2 Pertussis agglutinating antibodies

Agglutinating antibodies were measured according to SOP 12C-ALG-38 which is essentially the method as described by Manclark (44) using *B. pertussis* strain 3838 as antigen. US Pertussis antiserum (rabbit conc.) lot 2 was used as reference and a control serum was included on each plate. For each serum, a twofold dilution series in 8 wells was tested starting with 1:4 dilution. The results were considered valid if the titer of the control serum was

within one twofold dilution of its previously established titer. The agglutination titer is expressed as the reciprocal of the highest final dilution of serum resulting in agglutination. Sera negative at the starting dilution were scored as 2 for calculation purposes.

2.5.3 Poliovirus neutralising antibodies

Neutralising antibody titers against poliovirus strain 1(Mahoney), 2 (MEF) and 3 (Saukett) were determined according to SOP 17C-IPV11 in essence describes the micro-neutralisation assay by Albrecht et al (2). Each serum was titrated in a twofold dilution series in 12 wells with 100 $CCID_{50}$ of the virus starting at 1 : 2 dilution. The results were considered valid if the titer of the control serum on each plate was within the 95% confidence interval. Titers are expressed as the ^{2}log reciprocal of the highest final dilution of serum resulting in neutralisation. Sera negative at the starting dilution were assigned the value of 1.

2.5.4 IgA-whole cell ELISA

The measurement of IgA antibodies was performed as described by Nagel et al (54, 55) and SOP LBA/M-205 with a crude cell-membrane preparation from 3 different *B. pertussis* isolates. The sera were tested at a 1: 100 and 1: 400 dilution with an internal RIVM standard serum as reference. Titers are expressed as arbitrary units/ml with the negative sera assigned the value of 1. The antigens were prepared following the procedure SOP LBV/13C-PER-01.

2.5.5 Diphtheria and Tetanus antitoxin antibodies

Anti Diphtheria and Tetanus antibodies were measured with the ToBI assay according to SOP 12C-ALG-35 as described earlier by Hendriksen et al (35). Twofold dilutions of sera in 10 wells were preincubated with a fixed amount of toxin and the remaining free toxin is determined in plates coated with a polyclonal antitoxin antibodies. Results were expressed in IU/ml with the use of an internal RIVM standard serum as reference, calibrated on the WHO reference serum. On each plate a control serum was also included. Calculation and acceptance of the results was performed as described in paragraph 2.7.1. The minimum level of detection was 0.01 IU/ml and sera with titers below this level were assigned the value of 0.005 IU/ml.

2.6 Adverse events

Because of the open design of the study possible bias in observation and appreciation of adverse events could not be avoided. Therefore the study has on this aspect a more observational than a controlled character.

All general practitioners in the study area were informed about the study and the possible adverse events. Parents were supplied with a diary in which to record all observed adverse events in three time periods, the first 24 hours, the second to third day and the fourth to seventh day following vaccination. This included systemic symptoms as feverishness with recorded rectal temperature, listlessness, crying, anorexia, nausea, headache and general skin symptoms. Also local reactions as redness and swelling, pain, itching and diminished use of the arm. A digital thermometer and a measuring scale were supplied.

The observed adverse events were put down on the CRF after the telephone interview by a physician (18-30 hours after the vaccination) and at the time of the second blood sampling, when any other adverse events were also reviewed.

2.7 Data analyses and statistics

2.7.1 Antibody response

Because the data displayed outliers and seemed very skewed, the serological analyses were performed on logarithmically (ln) transformed data except for polio (reciprocal ^{2}log). Pre- and postvaccination geometric mean antibody titers (GMTs) in the eight study groups were compared using One-way Anova.
An immune response to vaccination was defined as at least a fourfold increase of the prevaccination antibody value. Moreover, the post vaccination titer should be at least fourfold greater than the minimum detectable level. For the pertussis antigens PT, FHA, PRN, Aggl. and FIM the percentages of participants showing an immune response were calculated as well as for D, T and polio. As protective titers the cut-off value of 0.1 IU/ml was used for diphtheria and tetanus and 3 (reciprocal ^{2}log) for polio (22, 23, 41, 68, 70).
To analyse the development of antibody levels, the differences of the ln-transformed post- and prevaccination antibody titers were calculated. Multiple linear regression models were built with these differences as dependent variables. Indicator variables were used as independent variables for:

1. whole cell Pertussis; study groups DTP-IPV & DTP-IPVv
2. acellular Pertussis; study groups ACV-SB, ACV-SBv, ACV-WL & ACV-PM
3. Smithkline Biologicals; study groups ACV-SB & ACV-SBv
4. Wyeth Lederle/Takeda; study group ACV-WL
5. Pasteur Merieux MSD; study group ACV-PM
6. Polio-vero; study groups DT-IPVv, DTP-IPVv & ACV-SBv

The forward variable selection method was used (for more detailed information see appendix).
No indicator variable for different diphtheria antigen content was used because it was completely confounded by the WCV-indicator. Thus, any effect apparently attributable to the whole cell pertussis vaccine component may also have been caused by the extra diphtheria dose. For analysis the software programme SPSS version 7.0 was used.

2.7.2 Adverse events

Local and systemic adverse events were recorded for the seven days following vaccination. The occurrence of adverse events in all eight groups are compared, with DT-IPV as control group, by calculating Odds Ratio's with 95% confidence intervals (OR +95%CI). To assess association of specific adverse events with vaccines/vaccine components a logistic regression model was used. Indicator variables were included as independent variables:

1. whole-cell pertussis containing vaccines, groups DTP-IPV and DTP-IPVv
2. acellular pertussis containing combinations, groups ACV-SB, ACV-SBv, ACV-WL or ACV-PM
3. polio-vero containing combinations, groups DT-IPVv, DTP-IPVv and ACV-SBv

For the different diphtheria contents of the vaccines no indicator variable could be used, since this was fully associated with the whole-cell pertussis component.
The occurrence of a specific adverse event at any time in the seven days following vaccination was the dependent variable. All dependent variables were dichotomised.
For the groups with an acellular pertussis vaccine for local reactions the combined local reactions of the left and or the right arm were used.

2.8 Study monitoring

The study was monitored by a full-time monitor from Parexel-MIRAI ®, a contract clinical research organisation in Amsterdam. During the clinical stages of the study, monitoring visits were made to all study sites (CB’s) to guard protocol adherence. In addition, all informed consent papers and CRF's were checked for correct and complete data.

3. Results

3.1 Study population

A total of 244 parents responded to the invitation to participate in the study. After additional information was given and after evaluation of the inclusion and exclusion criteria, 180 children were enrolled in the study and an informed consent was obtained from all parents. These participants were randomized to one of the 8 study groups (Table 2). The children have been recruited from a total population of approximately 2000 children living in the area where preventive child health care was provided by the 'Stichting Thuiszorg Oost-Veluwe'.

For one of the participants earlier pertussis disease was reported. After vaccination, one participant was lost to follow-up. Pre- and postvaccination blood samples were not obtained from one participant, and postvaccination samples from two participants. However, data about adverse events were not missing for these children. In two children, the post vaccination blood samples obtained were too small to determine all antibody parameters, so anti-diphtheria and anti-tetanus antibodies testing had to be omitted (see paragraph 2.7). One participant was excluded for the serological analyses, because the interval between vaccination and bloodsampling was too small (3 weeks).

Table 2. Number and sex of participants by study group

Study group	Male	Female	Total
DT-IPV	10	13	23
DTP-IPV	10	11	21
DT-IPVv	12	10	22
DTP-IPVv	9	14	23
ACV-SB + DT-IPV	15	8	23
ACV-SB + DT-IPVv (=ACV-SBv)	11	10	21
ACV-WL + DT-IPV	12	11	23
ACV-PM + DT-IPV	13	11	24
Total	92	88	180

3.2 Antibody response

All data from the different antibody assays are listed in the appendix. Geometric mean titers (GMT) with 95% confidence intervals were calculated for antibodies directed against the six pertussis antigens (PT, FHA, PRN, Aggl., FIM and IgA-WC), diphtheria toxin, tetanus toxin and against poliovirus type 1, 2 and 3 before and after vaccination in the eight different vaccine groups (Table 7 in appendix). The impact of the vaccination with the different vaccines is illustrated in Figure 1.
Prevaccination titers were similar in the eight groups for PT, FHA, PRN, IgA-WC, diphtheria, tetanus and polio type 3. For Aggl. and FIM a statistically significant difference in the prevaccination titers between the groups was observed (One-way Anova; $p<0.05$). The pretiters for Aggl. and FIM were higher in the ACV-SBv group and also somewhat higher in the DT-IPV group compared to the other groups.



Figure 1. GMT's before and after vaccination (light and dark blue) directed against PT, FHA, PRN, Aggl. FIM and IgA-WC from pertussis, poliovirus type 1, 2 and 3 and diphtheria toxin and tetanus toxin. GMT's are expressed as EU/ml for PT, FHA, PRN and FIM, as reciprocal titres for Aggl., as U/ml for IgA, as IU/ml for D and T and as ^{2}log reciprocal titres for polio. GMT values are indicated in the figure and 95% confidence intervals are indicated. Children in the ACV groups were given also DT-IPV vaccine. Note that GMT's are rounded up/off in the graphs.


Pertussis Toxin
GMT
200
180
160
140
120
100
80
60
40
20
0
2 3 2 7 1 1 2 8 2 56 2 77 2 91 2 91
DT-IPV
DTP-IPV
DT-IPVv
DTP-IPVv
ACV-SB
ACV-SBv
ACV-WL
ACV-PM


Filamentous Hemagglutinin
GMT
600
500
400
300
200
100
0
9 9 6 38 4 4 6 32 7 212 9 269 6 271 8 172
DT-IPV
DTP-IPV
DT-IPVv
DTP-IPVv
ACV-SB
ACV-SBv
ACV-WL
ACV-PM


Pertactin
GMT
250
200
150
100
50
0
8 8 6 32 6 6 7 31 6 146 9 140 6 72 6 8
DT-IPV
DTP-IPV
DT-IPVv
DTP-IPVv
ACV-SB
ACV-SBv
ACV-WL
ACV-PM


Agglutination
GMT
300
250
200
150
100
50
0
22
31
14
134
15
12
15
133
18
17
42
43
9
57
13
33
DT-IPV
DTP-IPV
DT-IPVv
DTP-IPVv
ACV-SB
ACV-SBv
ACV-WL
ACV-PM


Fimbriae
GMT
35
30
25
20
15
10
5
0
3
3
1
16
2
1
2
14
2
2
4
5
1
9
1
3
DT-IPV
DTP-IPV
DT-IPVv
DTP-IPVv
ACV-SB
ACV-SBv
ACV-WL
ACV-PM


IgA
GMT
16
14
12
10
8
6
4
2
0
2
2
1
8
2
2
2
9
1
1
2
3
2
2
1
2
DT-IPV
DTP-IPV
DT-IPVv
DTP-IPVv
ACV-SB
ACV-SBv
ACV-WL
ACV-PM


Polio type 1
GMT
18
16
14
12
10
8
6
4
2
0
9 14
10 14
8 14
10 15
10 15
10 14
9 14
9 14
DT-IPV
DTP-IPV
DT-IPVv
DTP-IPVv
ACV-SB
ACV-SBv
ACV-WL
ACV-PM


Polio type 2
GMT
18
16
14
12
10
8
6
4
2
0
8 15
9 15
8 15
9 16
9 16
9 16
9 15
8 15
DT-IPV
DTP-IPV
DT-IPVv
DTP-IPVv
ACV-SB
ACV-SBv
ACV-WL
ACV-PM


Polio type 3
GMT
18
16
14
12
10
8
6
4
2
0
7 14
7 13
6 14
7 16
8 15
8 15
7 14
6 14
DT-IPV
DTP-IPV
DT-IPVv
DTP-IPVv
ACV-SB
ACV-SBv
ACV-WL
ACV-PM

Antibody titers for polio virus type 2 were marginally different before vaccination (One-way Anova; $p<0.05$) probably due to fluctuations in titers and the small number of children in the groups. After vaccination all titers for the six pertussis antigens, diphtheria and for polio type 3 were significantly different between the 8 groups (One-way Anova; $p<0.05$). The titers for tetanus, polio type 1 and 2 did not show this difference.

3.2.1 Pertussis antigens

The number of participants who responded with a fourfold rise in the immune response (IgG antibody titer) to the pertussis antigens PT, FHA, PRN, FIM and Aggl. is shown in Table 3. The percentages with the fourfold rise is illustrated in Fig. 2, where no distinction was made between the IPV-MK and IPV-vero groups. The immune response to PT after vaccination was good for all 3 ACV's (=90% with a fourfold rise), while the WCV only scored 45% (see Fig. 2).
A similar high result was obtained with the ACV's for the response to FHA (=95%) and PRN (=90%) except for ACV-PM in the latter case because the vaccine does not contain PRN. The WCV gave a better response for these two antigens (FHA 70% and PRN 60%) than for PT. The fourfold rise in response to Aggl. and FIM after vaccination with ACV-WL amounts to =60%. The ACV-PM gives a fourfold rise to these antigens in 17% of the children, which is remarkable because this vaccine does not contain FIM. The WCV performed good for the Aggl. and FIM titers resulting in a percentage =85% of the children with a fourfold rise.

In the DT-IPV group 2 children showed a fourfold rise in the PT-titer (see Fig. 2). One child was probably infected with *B. pertussis* during the month between the first (prevaccination) and the second (postvaccination) blood sample because the other pertussis antigen titers were also elevated except PRN (see appendix 4). The other child already had high titers in the prevaccination sample except for PT suggesting a recent *B. parapertussis* infection. In the same vaccine group 4 other children showed an isolated fourfold rise in the agglutination titer, while the other pertussis antigens showed no rise. No explanation could be given for the rise of the agglutination titer in these cases but the sometimes rather difficult, subjective reading procedure of this assay might be the reason.

Table 3. Number of participants showing a fourfold rise in immune response against the different pertussis antigens

antigen →		PT	FHA	PRN	Aggl.	FIM
study group	N	n	n	n	n	n
DT-IPV	23	2	1	0	3	1
DTP-IPV	21	8	15	13	18	18
DT-IPVv	22	0	0	0	2	0
DTP-IPVv	23	10	16	12	20	16
ACV-SB + DT-IPV	23	21	21	21	1	1
ACV-SB + DT-IPVv	21	20	21	19	1	0
ACV-WL + DT-IPV	23	19	22	20	15	14
ACV-PM + DT-IPV	24	23	23	0	8	4



Figure 2. Percentage of participants showing an fourfold immune response against the different pertussis antigens (due to missing samples valid percentages are indicated).

To assess the effect of the different vaccines/vaccine components (WCV, ACV-SB, ACV-WL and ACV-PM) on the development of antibody titers, multiple linear regression was used. Table 4 shows the statistically significant regression coefficients for all measured antigens. After vaccination with DTP-IPV, the regression coefficient for Aggl. is 2.19, i.e. vaccination with WCV leads to a $e^{2.19}$ = 9-times increase in agglutination antibody titer when compared to vaccination without WCV. This method provides a clear picture of the vaccination effect evoked by the different vaccines/vaccine components on the different antibody titers, separately. Vaccination with WCV resulted in a large increase of the

Table 4. Association between antibody levels and vaccine components, as measured by regression coefficients (only statistically significant regression coefficients (r.c.) and p-values are shown)

Antibody	**Aggl**	**FIM**	**IgA**	**PRN**	**FHA**	**PT**	**dipht**	**tet**	**polio 1**	**polio 2**	**polio3**
DTP-IPV											
r.c.	2.19	2.24	1.63	1.72	1.82	1.38	0.88	-	-	-	-
p	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001				
ACV-SB											
r.c.	-*	-	-	3.06	3.30	3.52	-	-	-	-	-
p				<0.001	<0.001	<0.001					
ACV-WL											
r.c.	1.77	1.93	-	2.61	+0.56**	3.52	-	-	-	-	-
p	<0.001	<0.001		<0.001	0.02	<0.001					
ACV-PM											
r.c.	0.90	0.91	-	-	3.30	3.52	-	-	-	-	2.13
p	<0.001	<0.001			<0.001	<0.001					0.01
P_{vero}											
r.c.	-	-	-	-	-	-	-	-	-	-	1.65
p											<0.01

* no statistically significant regression coefficient (r.c.).

** regression coefficient is similar for all acellular vaccines (3.30), however for ACV-WL an additional regression coefficient of 0.56 was found

agglutination antibody titer compared to DT-IPV. The vaccination with ACV-WL and ACV-PM also showed an increase in Aggl. antibody titer but smaller, while vaccination with ACV-SB yielded no statistically significant increase as this vaccine does not contain this component. A similar vaccination effect was observed for FIM antibody titers (see table 4). Vaccination with ACV's caused large increases in PT-, FHA- and PRN antibody titers compared to DT-IPV, except for ACV-PM in case of PRN, as this vaccine does not contain PRN. ACV-WL caused even a significantly higher response to FHA than ACV-SB and ACV-PM. Vaccination with WCV caused smaller increases in the antibody titer against these 3 Pertussis antigens.
It is in this study not possible to distinguish between the WCV component and the effect of the other components of combined vaccines or of interaction/potentiation between the different vaccine components. The linear regression model does not allow this distinction either.
A similar picture was obtained when the increase in GMT between postvaccination and prevaccination for the 6 pertussis antigens was calculated as GMTpost/GMTpre. This increase is clearly visualised in Fig 3. It is important to keep in mind that the increase in ratio post/pre GMT only gives a broad outline of the effect of the different vaccines while the linear regression method was performed weighing all the participants individually.

The correlation between the different pertussis antigen assays was also analysed. A good correlation was only found between the Agglutination assay and the Fimbriae ELISA resulting in R=0.894 for all samples in the study. For the other antigens no good correlation could be observed even between PT, FHA and PRN (data not shown).



Figure 3. Rise in GMT of postvaccination titers compared to prevaccination titers for the pertussis antigens (x-axis) evoked by the 4 vaccines (y-axis). On the z-axis the ratio post/pre is indicated.

3.2.2 IgA-WC

IgA-antibody titers only rose after vaccination with DTP-IPV (5-fold increase, see table 3). From the 43 children in the DTP-IPV and DTP-IPV_v groups 16 showed an increase between pre- and postvaccinaton sample in their titer to a level =10 U/ml, while 17 others also had a rise in their titers but smaller (=5 U/ml). In all the other vaccine groups only one child showed a significant increase in its IgA titer to a level of 10 U/ml and three children a smaller increase (level between 3 and 6 U/ml). The IgG titers to the other Pertussis components in the DTP-IPV groups showed generally a good increase with the exception of PT where an increase to a level =10 U/ml was observed only in 18 out of 43 children. From these 18 children only 7 had significant elevated postvaccination titers for both IgA to *B. pertussis* and IgG to PT.
From the total of 180 participants, 15 children spread over the different groups had elevated IgA titers in their pre- as well as postsamples which may indicate on a recent natural infection. In 6 children a significant elevated titer to a level =10 U/ml was observed, while the other 9 showed a smaller increased level (=4 U/ml).

3.2.3 Diphtheria and Tetanus

The immune respons to diphtheria was very good and similar for the DT-IPV and the ACV groups (see Fig 1). The DTP-IPV group however showed a 2-fold increase compared to the other vaccine groups (table 4). The immune response to tetanus was also very strong and similar for all vaccine groups (Fig.1). None of the vaccine groups showed a significant difference in the rise in tetanus titers after vaccination (see table 4).
Before immunisation, 70 children (39.3%) had antibody levels <0.1 IU/ml to diphtheria and 32 children (18.0%) to tetanus. After vaccination, 8 children did not show a fourfold titer rise of diphtheria toxin antibodies and 9 children for tetanus. Thus the percentage with a fourfold rise amounted to =95%. From this group, 4 children had high pre-titers for diphtheria and 6 children for tetanus.
From the same group, 4 children did not show a titer rise both for diphtheria and tetanus and one child of these 4 had high pre-titers. From these 4 children, one child was still not protected against diphtheria, and one child was not protected against both diphtheria and tetanus (antibody levels <0.1 IU/ml). These 2 children were offered an additional DT-IPV vaccination.

3.2.4 Polio

The postvaccination titers to all three poliomyelitis strains were very high (note that the GMT's are expressed as a reciprocal ^{2}log in figure 1). There was only a small difference in immune response to the vaccine groups DTP-IPVvero and IPV-MK + ACV-PM for Polio type 3 (see Fig. 1 and table 4). For all other groups no difference was found between the IPVvero and IPV-MK for the three polio strains. In the DTP-IPVvero group the difference between the pre and post titer to polio type 3 was 1.65 (no ln, see paragraph 2.7.1) and after vaccination with DT-IPV+ACV-PM this difference was 2.13. When the results from the IPV-MK and IPVvero from the different groups were combined (5 and 3 groups, respectively) the GMT's were similar for pre and post samples for the three polio types with the exception of the post polio type 3 titers (table 5). A small but significant difference was found in favour of IPVvero for polio type 3. Remarkably, the GMT's for polio type 2 were slightly higher than for polio type 1. The percentages of the children with a fourfold rise after vaccination

Table 5. Geometric mean titers with 95% confidence interval in IPV-MK and IPVvero groups expressed as reciprocal ^{2}log titers.

		polio type 1		polio type 2		polio type 3	
		GMT	95%CI	GMT	95%CI	GMT	95%CI
IPV-MK	pre	9.39	[8.92-9.85]	8.53	[8.06-8.99]	6.84	[6.34-7.34]
	post	14.29	[13.85-14.73]	15.23	[14.76-15.67]	13.80	[13.34-14.26]*
IPVvero	pre	9.48	[8.84-10.12]	8.59	[8.07-9.12]	6.74	[6.07-7.40]
	post	14.25	[13.68-14.82]	15.77	[15.16-16.37]	14.91	[14.26-15.56]*

* statistically significant difference between IPV-MK and IPVvero (t-test $p<0.01$)

amounted up to 88, 93 and 95% for type 1, 2 and 3, respectively. The children that did not show a fourfold rise in titer had already very high pretiters. Before vaccination only 6 children were not protected against type 3 and after vaccination all children were protected.

3.3 Adverse events

For each study group both systemic adverse events and injection site reactions were recorded for the seven days following the vaccination. No serious adverse events occurred and no children were hospitalised and none were seen by a physician because of an adverse event. Sixteen children received paracetamol at any time in the first three days, mainly for fever and pain, thirteen in the whole-cell pertussis vaccine groups, two in the DT-IPV groups and one of the recipients of an acellular pertussis vaccine.
Frequency and severity was highest in the first 24 hours after vaccination and declined thereafter. In most children the symptoms lasted for one day or less. The most frequent complaint lasting into the second observation period was listlessness, in the majority without other systemic discomfort (25 cases). None of the children had continuation of systemic symptoms in the 4-7 day period. Therefore only symptoms in the first three days are presented.
The incidence rates of the systemic adverse events in the first day and the second-third day period for the different study groups are shown in Fig. 4A. The local reactions are displayed in Fig. 4B. Valid percentages are given (see for detailed recordings of adverse events Table 8A and Table 8B of the appendix). For comparison between the different groups the local reactions of the left arm in the WCV groups were compared with the accumulated reactions of the left and right arm in the ACV groups. The Odds Ratio's are given in Table 6**.**

Systemic and local symptoms were prominent in the whole-cell combination vaccine recipients, both in frequency as in severity or duration.
Fever, with recorded temperature $\geq$38.5°C occurred in 18/44 (40%) children at any time during the three days following the vaccination, in 5 children for more than one day. In the acellular pertussis vaccine recipients fever occurred in 3/91 (3.3%) children and in the DT-IPV groups in 2/45 (4%) cases, once for more than one day. The highest temperature recorded was 40.0°C in the WCV groups and 39.8 °C in the ACV or DT-IPV groups. With inclusion of low grade elevated body temperature ($\geq$37.5°C) the respective numbers are 28/44, 7/91 and 5/45 (62%, 8%, 11%).



Figure 4A. Systemic adverse events occurring in percentages of children in the different vaccine groups.



Study groups:

1 DT-IPV
2 DTP-IPV
3 DT-IPVv
4 DTP-IPVv
5 ACV-SB + DT-IPV
6 ACV-SB + DT-IPVv
7 ACV-WL + DT-IPV
8 ACV-PM + DT-IPV

Figure 4B. Local adverse events occurring in percentages of children in the different vaccine groups for the three observation periods (day 1; 2-3; 4-7).

Listlessness and crying occurred in 69-80 % of whole-cell pertussis combination vaccine recipients often accompanied by loss of appetite, with much lower frequencies in the other group with 15-30% and 9-27% respectively in the ACV and DT-IPV groups (see table 6 for frequencies and Odds Ratio's). Nausea and skin manifestations were rare events in all study groups.
Local reactions were also much more common in the WCV groups as was the severity and duration of the symptoms. Of the children in the WCV groups 23 experienced local redness for more than one day of which 10 extended into the third observation period. Swelling was less frequent and of shorter duration. Tenderness was very frequent and lasted in 28/44 cases for more than one day with in 9 cases into the third observation period. This was in the majority of cases accompanied with diminished use of the affected arm 35/44 which lasted in 18/44 for more than one day and in 4 cases more than 3 days. Injection site reactions for acellular vaccines and DT-IPV were much less frequent.
For the DT-IPV-only group redness and swelling occurred in up to 4% and keeping the arm still in 13 % with noted pain in 42 %. Only once pain lasted for more than one day.
The DT-IPV injection site reactions in the ACV groups were for redness and swelling 3.3-6.7% with pain in 25% and diminished use of the arm in 11%.
For the ACV injection site the aggregated local reactions were slightly lower with redness and swelling in up to 5.5% and pain and still arm in 18.7% and 7.7% respectively.

Logistic regression analyses was used to assess the association of the specific vaccines or components and the occurrence of specific adverse events. Fever, listlessness, crying, anorexia and headache occurring at any time during the seven day follow-up were used as dependent variables. As were the local reactions redness, swelling, pain or diminished use of the affected arm. As dummy variables were used WVC component containing vaccines, ACV component vaccines and IPV-vero component containing vaccines. Fever, headache, listlessness, crying and loss of appetite were significantly more prevalent in the WCV containing vaccine groups than in the groups with ACV and /or DT-IPV. This difference was most prominent on the first day and for listlessness still statistically significant in the second observation period. The effect of WCV containing vaccines on the four injection site symptoms was also statistically significant.

Table 6. Proportion and Odds Ratio's of adverse events in DTP-IPV and ACV groups vs. DT-IPV-groups

Symptom	**DT-IPV**	**DTP-IPV**	**OR**	**[95%CI]**	**ACV**	**OR**	**[95%CI]**
General adverse events							
fever (=38.5°C)	2/44	18/44	14.54	[3.12-67.86]	3/91	0.72	[0.12-4.45]
headache	1/44	10/44	12.65	[1.54-103.72]	7/90	3.63	[0.43-30.44]
listlessness	12/45	36/44	12.38	[4.50-34.03]	27/91	1.16	[0.52-2.58]
crying	4/45	31/44	24.44	[7.26-82.29]	11/91	1.41	[0.42-4.70]
loss of appetite	8/44	30/44	9.64	[3.57-26.07]	10/91	0.56	[0.20-1.52]
Local symptoms							
redness	1/45	33/44	132.00	[16.22-1073.93]	6/91	3.11	[0.36-26.61]
swelling	2/45	15/44	11.12	[2.36-52.33]	6/91	1.52	[0.29-7.84]
not using arm	6/45	35/44	25.28	[8.17-78.20]	13/91	1.08	[0.38-3.07]
pain	13/45	41/44	33.64	[8.83-128.20]	29/91	1.15	[0.53-2.51]

It is in this study not possible to distinguish between the WCV component and the effect of the other components of combined vaccines or of interaction/potentiation between the different vaccine components. The logistic regression model does not allow this distinction either.
There was no statistically significant difference between the groups receiving ACV and DT-IPV-only recipients, although there may be some attribution of ACV on systemic symptoms that could not reach statistically significance level because of the small numbers. For local symptoms the used model cannot distinguish between ACV and DT-IPV because the aggregated results of left and right arm together were used.
There was no statistically significant influence of IPVvero on systemic events.

4. Discussion

In the past few years several vaccine trials with a large number of ACV's in combination with DT have been performed (6, 7, 18, 20, 26, 28, 30, 39, 56, 61, 63, 76). Most of those studies involved the primary vaccinations in the first half year of life of the children and a booster at one year or in the second year of life. Only in a few trials ACV- and WCV-administration as a booster vaccination in children 4 to 6 years of age has been studied (3, 7, 8, 39, 59, 82). In this trial we have studied the immunogenicity and reactogenicity of 3 different ACV's given simultaneously with the regular DT-IPV and the RIVM-WCV in the combination vaccine DTP-IPV administered as a booster dose in children 4 years of age. Furthermore, the immune response of a new IPV (produced on Vero cells) was evaluated in comparison with the regular IPV (produced on MK cells) in the same group of children. The children in this study were previously immunized with 4 doses of the RIVM DTP-IPV (containing WCV and IPV-MK) at the age of 3, 4, 5 and 11 months.

4.1 Antibody responses

4.1.1 ACV

The GMT's of the pertussis antigens PT, FHA and PRN determined after vaccination with the 3 different ACV's in this study are in agreement with the titers observed in other trials with these vaccines (18, 28, 30, 56). All three ACV's induce an excellent response to the pertussis components that are included in the vaccines (fourfold rise in antibody titer = 90%). The near equal GMT-PT in the different ACV groups, despite the 8-fold lower PT content in ACV-WL may reflect the different detoxification procedures of PT. For FHA the antibody levels of the ACV-PM were slightly lower, although antigen content was equal for the different ACV's. The antibody responses to PRN do reflect the antigen contents of the different vaccines. The immune response to Aggl. and FIM in 30% and 15% of children vaccinated with ACV-PM is surprising since the vaccine is not supposed to contain FIM in sufficient amounts. But the response indicates that a small amount of fimbriae is likely to be present in this vaccine. In the ACV-WL group 4 out of 22 children had no response against FIM, probably reflecting the low content of this antigen in the vaccine. ACV-SB does not contain FIM and did not evoke an immune response.

4.1.2 WCV

The WCV groups showed a very broad immune response to all tested antigens. Especially the response to FIM and Aggl. with a fourfold titer rise was very good (up to 90%). The absolute titers against PT, FHA and PRN were considerably lower than observed for the ACV's, which reflects the smaller amounts of PT, FHA and PRN present in the RIVM-WCV. The lower GMT's may not be clinically relevant since conferred immunity is not reflected by the level of antibodies, especially in WCV recipients but also in ACV.
About 50% of the children in the WCV group did not respond at all to PT, but did respond to the other pertussis antigens. If the non-responders to PT are omitted from the WCV groups the GMT to PT doubles (21-48 EU/ml). Apparently, the booster vaccination with WCV induces a good or a non-detectable (all or nothing?) response against PT. The antigen content of PT present in the RIVM-WCV is low indeed due to the production procedures, purposefully introduced some decades ago (15). The production process for the RIVM-WCV was modified in 1996. This modification resulted in a better standardisation of the potency.

In the DT-IPV and the ACV-SB group a high GMT to Aggl. and FIM in the prevaccination samples was observed. This elevated level was maintained after vaccination but no rise was observed. Because of their composition these two vaccines are not likely to induce a rise in the Aggl. and FIM antibody titers. Therefore, the high GMT in the pre- and postvaccination samples must be due to the high titers of several children in these groups most likely induced by natural infection.

4.1.3 IgA

The presence of IgA antibodies reflects contact with *B. pertussis* (54). Elevated IgA titers were observed in the paired pre- and postvaccination samples of 15 children from the total study group (8%). In 5 of these 15 children the pre-titers were very suggestive for a recent *B. pertussis* infection (high titers for all the pertussis antigens as well as for IgA), in 4 cases for a *B. parapertussis* infection (high titers to all the pertussis antigens except PT) and in the other 6 the data were not so conclusive. These 15 children were evenly distributed over the different vaccine groups with the exception of the DTP-IPV and ACV-PM groups in which no significant elevated IgA titers in paired samples could be found.
On the contrary, in the DTP-IPV groups 32 out of 43 children showed a rise in the IgA titer after vaccination (=5 U/ml). From these 32 children only in 4 cases the prevaccination samples were also slightly elevated in IgA titer (4 to 7 U/ml). In one of these 4 the overall titers were suggestive for a recent *B. pertussis* infection. In a few cases from the 31 children the rise in IgA titer as well as in the other pertussis antigen titers was so dramatic that this might be caused by an infection intermittent with the study. However, parents did not report clinical symptoms of *B. pertussis* at the second blood sampling. None of the children of the ACV groups showed a substantial IgA response.
All the data taken together seem to indicate that vaccination with DTP-IPV causes a small but significant rise in the IgA titer in the serum of most children. The relevance of this titer increase remains to be investigated. It is interesting to determine the specificity of these IgA antibodies. According to the literature they should be directed largely against FHA (25) but preliminary results show that these IgA antibodies are directed not only against FHA but also against PRN and to a lesser extent against PT. Another very important question is whether there might be a link/correlation to an increase of the titer of secretory IgA on the mucosa of the respiratory tract.

4.1.4 D and T

The immune response to Diphtheria toxoid is significantly larger in the DTP-IPV groups than in the other vaccine groups. The greater amount of toxoid present in this vaccine (15 Lf versus 2.5 Lf in DT-IPV) and/or the adjuvant effect of the pertussis WCV-component on the diphtheria response in this combination vaccine can explain the larger titer increase. It should be realized that this adjuvant effect is lost of course should WCV be replaced by an ACV.
The immune response to Tetanus toxoid was also very good and no difference was observed between the groups.

4.1.5 IPV

The response to the IPV-MK and IPVvero was excellent against all three virus types. The small difference observed in the ACV-PM group for polio type 3 is probably due to a few low pretiters of some children in this group resulting in a low preGMT. When the data from all IPV-MK and all IPVvero vaccinations are compiled this difference was no longer observed due to the larger number of children in the groups. The difference in the response to polio

type 3 found in the DTP-IPVvero group was still significant after compiling the results from the different groups. This might reflect the difference in the amount of D-Ag of type 3 between the IPV-MK and IPVvero composition. The IPV-MK as a component of DT(P)-IPV was composed according to current Dutch guidelines (with a minimum of 20-2-3.5 D-Ag for type 1, 2 and 3, respectively) and the IPVvero to the international requirements (at least 40-8-32 D-Ag for the 3 strains). Both vaccines used in this study comply with these requirements (see table 1). While the twofold difference in the amount of polio type 2 present in the two vaccines seems to have no influence on the response, the fourfold difference in the amount of type 3 may result in a significant difference in response. However, the antibody titers after vaccination with both vaccines are so high that it is doubtful if such a difference will have any influence on protection.
Both vaccines perform very well in this study in which the children proved to be excellently primed. If both vaccines will contain a similar composition of the three strains, most probably no difference in response will be observed between them in future field trials.

4.2 Adverse events

In this study the rate of adverse events in the whole cell pertussis vaccine recipients was much higher than in the acellular pertussis vaccine recipients. This was to be expected since WCV is much more reactogenic than ACV. This difference is most pronounced in the frequent mild adverse reactions.
It was shown in the Sweden trial that the rarer more serious adverse events occurred in infants in near equal frequency following WCV and ACV (56). This study with four year old children is far to small to detect any adverse event that is relatively rare.
It should be stressed that even for the common adverse events this study does not provide for direct comparison of the whole cell pertussis component with the acellular component. The whole cell component is administered in a combination vaccine with known interaction whereas the acellular component vaccines are single vaccines.
So the results should be interpreted with some reservation. Also because possible attention bias may play a role since the study was not blinded and parents were advised on what to expect and how to deal with occurring adverse events. Although the WCV recipients had frequent systemic and local symptoms, generally there was only mild to moderate discomfort, mainly limited to the first day after vaccination. Compared to studies in infants, the rate of adverse events in this group of four year olds is favourable (64, 81). The results do not suggest higher reactogenicity of WCV in older children as is commonly believed (53). Considering the higher potency of the WCV component of the vaccine used in the current study this seems to be even less the case.
Comparing safety data between different studies is nearly always hampered by different designs, level of ascertainment and cut-off values. Differences in vaccine constituents other than the WCV may attribute substantially to observed differences in reactogenicity. In this study there does not seem to be significant differences in the rate of reactions between the IPVvero and IPV-MK containing vaccines.
In the light of the satisfactory serologic profile, with a very broad response to all tested antigens and the proven long-term effectivity of whole cell pertussis vaccines, it certainly seems worthwhile and feasible to invest in lowering the reactogenicity of the current vaccine (4, 5, 16, 45), which is necessary for maintaining the high acceptance of the RVP in the population. Additionally, programmatic adjustments like changing the injection site from M. Deltoideus to M. Triceps may alleviate local reactions to some extent. The use of profylactic paracetamol as is advised in some other countries may deserve attention also.

4.3 Considerations and recommendations

4.3.1 Booster response and memory

For the pertussis antigens, the titers after administration with acellular vaccines are high and comparable with other field trials where a 3 or 4 dose schedule with the last vaccination as booster is used. Titers of non-vaccinated children at 4 years of age are not known in the Netherlands due to the massive participation in the national immunisation programme. However, titers found after vaccinations with WCV at 3, 4 and 5 months (priming) and even at 11 months (booster) are much lower compared to the titers observed in this study (41, 80). It is obvious from the immune responses to the different vaccines/vaccine components measured in this study that the children are indeed primed by the vaccinations with the RIVM-WCV administered in the first year of life. This observation indicates that the 4 year old children have sufficient immunological memory to produce a good booster response. Moreover, it should be noted that in the serum of about 10% of children before and during the trial there were signs of natural *B.pertussis* or *B. parapertussis* infection. They showed high titers to all or almost all measured pertussis antigens. However, only one child reported clinical symptoms. So there is evidence that the RVP schedule and vaccine do protect against infection or colonization and prevent clinical symptoms or complications, again suggesting sufficient immunological memory for protection against natural infection. But it also shows that the risk of pertussis is high, and it stresses the importance of timely vaccination. For the RVP, it carries a warning against unnecessary postponement and omitting the pertussis component in the first four vaccinations.

4.3.2 Importance of antibodies

The persistence of high antibody levels after vaccination with ACV or WCV and natural infection is generally limited (26, 47, 79). The pretiters of antibodies directed against the different pertussis antigens were low in this study about 3 years after the previous pertussis immunisation, but also in other field trials it has been observed that the titers almost disappeared in not more than 2-3 years. It is not to be expected that there will be a difference in persistence of antibodies induced by the ACV and WCV vaccines used in this trial. It seems that in contrast with Diphtheria, Tetanus and in particular Polio vaccines, the pertussis antibody titers as a result of administration of ACV or WCV and even after natural infection have a much shorter half life. This is illustrated by the high rate of reinfections in the whole population and multiple subclinical or asymptomatic infections individually during life (84). In this respect, it should be noted that high titers as induced by ACV's do not necessarily mean better protection because these titers also rapidly decrease. Therefore, the importance of the antibodies is still under discussion: do they contribute to protection or not? Recently, in pertussis field trials in Sweden and Germany a correlation was found between the presence of antibodies in individuals and the degree of protection in 2 year follow-up studies. Both research groups came to the conclusion that besides PT also PRN and FIM antibodies seem to be relevant for protection (11, 79). The antibodies against FHA were found not to contribute to protection. These findings support historical data indicating that agglutinating antibodies are associated with protection (44) and suggest that anti-PT, anti-PRN and anti-FIM antibodies may be used as surrogate markers of protection. As a consequence antibodies really contribute to protection although, as it seems, on a short term basis because the titers against pertussis antigens rapidly decrease within 2-3 years (17, 27, 37, 65, 66). The vaccine induced protection against *B. pertussis* seems to last longer (5-10 years) than the measured antibody levels and upon subsequent natural infection the disease is much milder. Although

many biases can affect efficacy studies based on attack rates, in this manner calculated vaccine efficacy seems to amount to around 50% after 5 years (21, 38).

4.3.3 Polymorphism of *B. pertussis*

Another important point to take into consideration is the polymorphism in the virulence factors PT and PRN of *B. pertussis* found not only in the Netherlands but also in strains in other countries. There is accumulating evidence that the selection pressure caused by the vaccination programme during the past 45 years may have selected for strains carrying PRN and PT variants distinct from those found in the vaccine strains. This has already been proven for PT and PRN but is possibly also the case for other pertussis components (52). If this vaccine-driven evolution of *B. pertussis* should prove to be a major cause of the Dutch epidemic in 1996-97 (49), then the consequences for both WCV's and ACV's will be enormous, the route to further improve the pertussis vaccines will be longer and the shrew of pertussis even more difficult to be tamed (14).
In this respect, it should be noted that the ACV-WL contains FIM2 as vaccine component which is at the moment only present in the 10-20% of the circulating strains of *B. pertussis* in the Netherlands (80-90% of circulating strains contain FIM3). The RIVM-WCV is composed of two strains (509 and 134) which ensures the presence of both FIM2 and FIM3 in the vaccine. Both the WCV and the ACV's contain the variant PRN1 while the majority of the circulating strains of *B. pertussis* in the Netherlands since 1990 were found to contain variant PRN2 or PRN3 (43). Immunological effects of the antigenic differences found in PRN has been suggested in the results of proliferative T-cell responses (33, 51). A similar situation applies for the S1 subunit of PT with variants B and D present in all vaccines and mainly variant A in the circulating strains, but it should be noted that the polymorphism of PT is restricted to a conservative substitution of 3 amino acids (52).

4.3.4 Other parameters

It will be worthwhile to measure in these serum samples the biologically active, functional antibodies in more detail, like with the PT-assay in Chinese Hamster Ovary cells, inhibition of adhesion to epithelial cells, the subclass of the antibodies etc. Moreover, the samples can be used to localize immunologically important epitopes of PT, FHA and PRN with the use of monoclonal antibodies, synthetic peptides and affinity measurements.
In this field trial, heparinized blood samples were taken also in study groups DT-IPV, DTP-IPV and ACV-SB to study the influence of vaccination on the cellular immunity in more detail (29). In particular, the ability of T-cells to proliferate after stimulation with different peptides from the various pertussis antigens and the cytokine profile of these stimulated T-cells will be studied. All these studies can contribute to a better understanding of the correlates of protection in case of *B. pertussis* infection.

4.3.5 Possible effects of extra vaccination

Since 1953, when pertussis vaccination was introduced in the Netherlands, the whole cell vaccine has lowered the incidence of clinical pertussis tremendously. Protection has been most pronounced in young children in whom the rate of complications, sequelae and death is highest. There is probably also cross-protection against *B. parapertussis* (34).
Due to the recent epidemic (1996-1997) doubts have been raised about the efficacy of the WCV, but it was shown that there still is protection in the majority of the population and that vaccination reduced severity of symptoms. Most reported cases were seen in the 4-9 year old age group. It is debated that the inclusion of pertussis vaccine in the RVP at four years of age

will either or not diminish the substantial burden of disease in the (very) young children and may provide a substantial contribution to the prevention of epidemics, which is the long term purpose of such a booster vaccination (10).
In the USA there seems to be a shift in the important source of *B. pertussis* infection to older age groups in the child bearing age, who may transmit the disease to susceptible infants. It is hypothesized that this shift of infection is due to revaccination at 4-6 years of age, postponing natural reinfection at that age which might have caused a more solid long lasting immunity. The importance of this hypothesis needs to be further established (1).
Whether including pertussis vaccine in the regular schedule in the four year olds will effectively lower clinical pertussis incidence in young children in the Netherlands remains to be seen. An extra pertussis vaccination at this age will probably decrease *B. pertussis* circulation in siblings of young infants. It is not very likely, however, that it will decrease the circulation among parents of babies in the Netherlands-with an average age of mothers of first-borns near thirty- contrary to suppositions made in other countries. There is accumulating evidence that persisting immunity in vaccinated populations depends on subclinical or mild infections to booster waning immunity in later years (21). These infections seem to occur more frequently in elderly children and adults than has been commonly recognized. These individuals may function as a major reservoir for transmission of pertussis to infants too young to be vaccinated (13, 17, 21).

4.3.6 Choice of pertussis vaccine for 4 year old children

On the basis of this study and the serological results it is not possible to make a choice between the three different ACV's, because they all show very good responses reflecting their variable composition, but a high titer level is not related directly to protection. Moreover the data available about long term efficacy of different ACV's are limited yet (62, 76). It seems reasonable based on former trials to prefer an acellular vaccine with the most pertussis components (18, 28, 56). The necessary incorporation of any acellular vaccine into a combined DT-IPV vaccine will take time and further field trials. As discussed by Gangarosa et al., the choice between WCV and ACV involves trade-offs between safety, efficacy, practicality, and cost (24). In addition to fewer mild adverse events, acellular vaccines could interrupt disease transmission by means of their potential use in adolescents and adults. However, the best acellular vaccine may not provide protection equal to that of the best whole-cell vaccines (62). Replacement of WCV with ACV might conceivably lead to less effective control at substantially higher costs (24).

If it is considered necessary in the control of B. pertussis and for protection of the most vulnerable age group, to include pertussis vaccination of the four year olds immediately, then the easiest, fastest and cheapest way is to use the regular DTP-IPV vaccine. Despite the relatively high rate of common adverse events, the balance of the safety profile and the broad immunogenicity profile and long term proven effectivity of the whole cell pertussis vaccine components seem to warrant such a choice. Moreover it will save the children of this age group the emotional stress of a second injection and some additional injection site complaints and it will save money and time because it will be just one injection. If a multicomponent acellular vaccine is chosen for the booster dose the ACV with the most components should be preferred and a combination with the regular DT-IPV seems a requirement to guarantee a single injection for the 4 year old children.

4.4 Conclusion

The main goal of this study was to investigate whether a booster response could be induced after vaccination with acellular and whole cell pertussis vaccines in children primed with WCV and to demonstrate whether the two polio vaccines induced similar booster responses. In general, the answer to those two questions can be positive for all vaccines.

With respect to pertussis, after vaccination with the ACV's almost all the titers are high against the different pertussis components and generally reflect the composition of these components present in the vaccines. The titers are comparable with those observed in other trials with these vaccines. After vaccination with the WCV the titers against Aggl. and FIM are good, against FHA and PRN still reasonable but against PT they are low. The reason for this is perfectly clear. The amount of PT was kept as low as possible in the vaccine for historical reasons as this was believed to prevent serious adverse events. Therefore, half of the children vaccinated with WCV showed no PT-booster reaction and the GMT of PT for the other half was reasonable. On the other hand, the response to the WCV was broad as expected but also showed an unexpected IgA-response in the majority of the children. A drawback of the WCV is the rate of adverse events, although mostly mild and of limited duration. This may hamper the acceptance of the vaccine in the population. But this will almost certainly be the case if there is a need for two injections instead of one. The emotional upset and pain and additional injection site reactions will have to be taken into account in the trade-off between different pertussis vaccines, as will be the costs of purchase, production and of the (extra) time needed by the vaccine administrators.

With respect to polio, the answer is far less complex. Both the IPV-MK and the IPVvero have proven to induce excellent booster responses in this trial. Although the composition of the vaccines was not identical, the protection after the booster vaccinations with the IPVvero produced under the international requirements will be as good or even better as achieved with the present vaccine.

References

1. Advisory Committee on Immunization Practices (ACIP); Hospital Infection Control Practices Advisory Committee (HICPAC). Immunization of Health-Care Workers: Recommendations of the Advisory Committee on Immunization Practices. MMWR, 1991, Vol. 40 (No. RR-13): 1-25.
2. Albrecht-P; van Steenis-G; van Wezel-AL; Salk-J. Standardization of poliovirus neutralising antibody tests. Rev. Infect. Dis., 1984, Vol. 6:S540-546.
3. Annunziato-PW; Rothstein-EP; Bernstein-HH; Blatter-MM; Reisinger-KS; Pichicero-ME. Comparison of a three-component acellular pertussis vaccine with a whole-cell pertussis vaccine in 4-through 6-year-old children. Arch. Ped. Adol. Med., 1994, Vol. 148: 503-507.
4. Auerbach-BS; Lake-AM; Wilson-ME; Willingham-FF; Shematek-J; Moulton-L; Deforest-A; Halsey-NA. Dose-Response to a Two-Component Acellular Pertussis vaccine in infants and comparison with Whole-cell vaccine. Biologicals, 1998, Vol. 26: 145-153.
5. Baraff-LJ; Manclark-CR; Cherry-JD; Christenson-P; Marcy-SM. Analyses of adverse reactions to diphtheria and tetanus toxoids and pertussis vaccine by vaccine lot, endotoxin content, pertussis vaccine potency and percentage of mouse weight gain. Pediatr. Infect. Dis. J., 1989, Vol. 8: 502-507.
6. Bégué-P; Stagnara-J; Vie-le-Sage-F; Bernard-JC; Xerri-B; Abitbol-V. Immunogenicity and reactogenicity of a booster dose of diphtheria, tetanus, acellular pertussis and inactivated poliomyelitis vaccines given concurrently with *Haemophilus* type b conjugate vaccine or as pentavalent vaccine. Pediatr. Infect. Dis. J., 1997, Vol. 16: 787-794.
7. Bernstein-DI; Smith-VE; Schiff-GM; Rathfon-HM; Boscia-JA. Comparison of acellular pertussis vaccine with whole cell vaccine as a booster in children 15 to 18 months and 4 to 6 years of age. Pediatr. Infect. Dis. J., 1993, Vol. 12: 131-135.
8. Bernstein-HH; Rothstein-EP; Pichichero-ME; Francis-AB; Kovel-AJ; Disney-FA; Green-JL; Marsocci-SM; Lynd-AM; Wood-GC; Schiller-RP; Girone-JAC; Hipp-TJ; Souder-RL; Kennedy-TI; Meschievitz-CK. Clinical reactions and immunogenicity of the BIKEN Acellular Diphtheria and Tetanus Toxoids and Pertussis vaccine in 4-through 6-year-old US children. Am. J. Dis. Child., 1992, Vol. 146: 556-559.
9. Bijkerk-H; Surveillance and control of poliomyelitis in the Netherlands. Rev. Inf. Dis., 1984, Vol. 6: S451-S456.
10. Cherry-JD; Brunell-PA; Golden-GS; Karzon-DT. Report of the Task Force on Pertussis and Pertussis Immunization, 1988.
11. Cherry-JD; Gornbein-J; Heininger-U; Stehr-K. A search for serologic correlates of immunity of *Bordetella pertussis* cough illnesses. Vaccine 1998, Vol. 16: 1901-1906.
12. Cherry-JD. Comparative efficacy of acellular pertussis vaccines: an analysis of recent trials. Pediatr. Infect. Dis. J., 1997, Vol. 16: 90-96.
13. Cherry-JD. The role of *Bordetella pertussis* infections in adults in the epidemiology of pertussis. Develop. Biol. Stand., 1997, Vol.89: 181-186.
14. Cohen-H. Pertussis "A shrew still to be tamed", Een onderzoek naar de kwaliteit van het kinkhoestvaccin, wat betreft immuniserende waarde en bijwerkingen geproduceerd in het RIVM (periode 1986-1997), Tussenrapport, Bilthoven.
15. Cohen-H; Nagel-J. Two injections of Diphtheria- Tetanus- Pertussis- Polio Vaccine as the backbone of a simplified immunization schedule in developing countries. Rev. Infect. Dis., 1984, Vol. 6: S350-1.

16. Decker-MD; Edwards-KM; Steinhoff-MC; et al. Comparison of 13 acellular pertussis vaccines: adverse reactions. Pediatrics, 1995, Vol. 86: 557-566, supplement.
17. Deen-JL; Mink-CA; Cherry-JD; Christenson-PD; Pineda-EF; Lewis-K; Blumberg-DA; Ross-LA. House-hold contact study of *Bordetella pertussis* infections. Clin. Infect. Dis., 1995, Vol. 21: 1211-1219.
18. Edwards-KM; Meade-BD; Decker-MD;et al. Comparison of 13 acellular pertussis vaccines: overview and serological response. Pediatrics, 1995, Vol. 86: 548-557, supplement.
19. Edwards-KM. Acellular Pertussis Vaccines – A Solution to the Pertussis Problem? J. Infect. Dis., 1993, Vol. 168: 15-20.
20. Feldman-S; Perry-CS; Andrew-M; Jones-L; Moffitt-JE. Comparison af acellular (B type) and whole-cell pertussis-component diphtheria-tetanus-pertussis vaccines as the first booster immunization in 15- to 24-month-old children. J. Pediatr., 1992, Vol 121: 857-862.
21. Fine-PEM; Clarkson-JA. Reflections on the efficacy of Pertussis vaccines. Rev. Infect. Dis., 1987, Vol. 9: 866-883.
22. Galazka-AM. The immunological basis for immunisation. Diphtheria. World Health Organization Geneva 1993, WHO/EPI/GEN/93.12.
23. Galazka-AM. The immunological basis for immunisation series. Tetanus. World Health Organization Geneva 1993, WHO/EPI/GEN/93.13.
24. Gangarosa-EJ; Galazka-AM; Wolfe-CR; Phillips-LM; Gagarosa-RE; Miller-E; Chen-RT. Impact of anti-vaccine movements on pertussis control: the untold story. Lancet, 1998, Vol. 351: 356-361.
25. Giammanco-A; Taormina-S; Genovese-M; Mangiaracina-G; Giammanco-G; Chiarini-A. Serological responses to infection with *B. pertussis*. Dev. Biol. Stand., 1997, Vol. 89: 213-220.
26. Giuliano-M; Mastrantonio-P; Giammanco-A; Piscitelli-A; Salmaso-S; Wassilak-SGF. Antibody responses and persistence in the two years after immunization with two acellular vaccines and one whole-cell vaccine against pertussis. J. Pediatr., 1998, Vol. 132: 983-988.
27. Granström-M; Olinder-Nielsen-AM; Holmblad-P; Mark-A; Hanngren-K. Specific immunoglobulin for treatment of whooping cough. Lancet, 1991, Vol. 338: 1230-1233.
28. Greco-D; Salmaso-S; Mastrantonio-P; et al. A contolled trial of two acellular vaccines and one whole-cell vaccine against pertussis. N. Engl. J. Med., 1996, Vol. 334: 341-348.
29. Hall-E; Parton-R; Wardlaw-AC. Responses to acellular pertussis vaccines and component antigens in a coughing-rat model of pertussis. Vaccine, 1998, Vol. 16: 1595-1603.
30. Halperin-SA; Mills-E; Barreto-L; Pim-C; Eastwood-BJ. Acellular pertussis vaccine as a booster dose for seventeen- to nineteen-month-old children immunized with either whole cell or acellular pertussis vaccine at two, four and six months of age. Pediatr. Infect. Dis. J., 1995, Vol. 14: 792-797.
31. Hannik-CA. Reacties na revaccinatie van kleuters met DTP-IPV-vaccin. Berichten RIV 1965, 230-233.
32. He-Q; Viljanen-MK; Ölander-RM; Bogaerts-H; Grave de-D; Ruuskanen-O; Mertsola-J. Antibodies to filamentous hemagglutinin of and protection against whooping cough in schoolchildren. J. Infect. Dis., 1994, Vol. 170: 705-708.
33. He-Q; Minh-NNT; Edelman-K; Viljanen-MK; Arvilommi-H; Mertsola-J. Cytokine mRNA expression and proloferative responses induced by pertussis toxin, filamentous hemagglutinin, and pertactin of *Bordetella pertussis* in the peripheral blood mononuclear cells of infected and immunized schoolchildren and adults. Infection and Immunity, 1998, Vol. 66: 3796-3801.

34. Heininger-U; Stehr-K; Cherry-JD. The efficacy of a whole cell pertussis vaccine and fimbriae against *Bordetella pertussis* and *Bordetella parapertussis* infections in respiratory mouse model. Vaccine 1998, Vol. 13: 1255.
35. Hendriksen-CFM; van der Gun-JW; Kreeftenberg-JG. Combined estimation of tetanus and diphtheria antitoxin in human sera by the in vitro Toxin-Binding Inhibition (ToBI) test. J. Biol. Stand., 1989, Vol. 17: 191-200.
36. Hewlett-EL. Pertussis: current concepts of pathogenesis and prevention. Pediatr. Infect. Dis. J., 1997, Vol. 16: 78-84.
37. Hewlett-EL; Halperin-SA. Serological correlates of immunity to *Bordetella pertussis*. Vaccine, 1998, Vol. 16: 1899-1900.
38. Jenkinson-D. Duration of effectiveness of pertussis vaccine: evidence from a 10 year community study. B. M. J., 1988, Vol. 296: 612-614.
39. Kanra-G; Ceyhan-M; Vandevoorde-D; Bogaerts-H. Acellular pertussis diphtheria-tetanus-pertussis vaccine containing separately purified pertussis toxoid, filamentous haemagglutinin and 69 kDA outer membrane protein as a booster in children. Eur. J. Pediatr., 1993, Vol. 152: 478-83.
40. Kimura-A; Mountzouros-KT; Relman-DA; Falkow-S; Cowell-JL. *Bordetella pertussis* Filamentous Hemagglutinin: Evaluation as a protectove antigen and colonization factor in a mouse respiratory infection model. Infect. Immun., 1990, Vol. 58: 7-16.
41. Labadie-JL; Sundermann LC; Rümke-HC. Multi-center study of the simultaneous administation of DPT-IPV and Hib PRP-T vaccines. RIVM Report 124001003, Bilthoven, 1996.
42. Linnemann-CC; Ramundo-N; Perlstein-PH; Minton-SD; Englender-GS. Use of pertussis vaccine in an epidemic involving hospital staff. Lancet, 1975, Vol. 20: 540-543.
43. van Loo-IHM, van der Heide-GJ, Nagelkerke-NJD, Verhoef-J, Mooi-FR. Temporal trends in the population structure of *Bordetella pertussis* during 1949-1996 in a highly vaccinated population. J. Infect. Dis., 1999, Vol. 179: 915-932.
44. Manclark-CR; Meade-BD; Burstyn-DG. Serological response to *Bordetella pertussis*. Manual Clinical Immunology (third edition), 1986, 388-394.
45. McIntyre-P; Forrest-J; Heath-T; Burgess-M; Harvey-B. Pertussis vaccines: past present and future in Australia. CDI, 1998, Vol. 22: 125-132.
46. Meade-BD; Deforest-A; Edwards-KM et al. Description and evaluation of serologic assays used in a multicenter trial of acellular pertussis vaccines. Pediatrics, 1995, Vol. 86: 570-575, supplement.
47. Melker de-HE; Boshuis-HGL; Mommers-MPTM; Sundermann-LC; Labadie-J; Rümke-HC; Versteegh-FGA; Conyn-van Spaendonck-MAE; Schellekens-JFP. Serodiagnostiek van kinkhoest: interpretatie van hoge IgG/IgA concentraties in acute fase serum: (Her)evaluatie van eenpuntsserologie. RIVM report 128507003, Bilthoven, 1996.
48. Melker de-HE; Conyn-van Spaendonck-MAE; Schellekens-JFP. Pertussis surveillance 1989-1995. RIVM report 128507004, Bilthoven, 1996.
49. Melker de-HE; Conyn-van Spaendonck-MAE; Schellekens-JFP. The pertussis epidemic in 1996; description and evaluation based on surveillance data from 1976 to 1996. RIVM report 128507005, Bilthoven, 1997.
50. Mensinga-TjT; Labadie-J; Rümke-HC; Meulenbelt-J. Phase I-II clinical study of IPV-Vero vaccine. RIVM report 124001001, Bilthoven, 1995.
51. Minh-NNT; Edelman-K; He-Q; Viljanen-MK; Arvilommi-H; Mertsola-J. Antibody and cell-mediated immune responses to booster immunization with a new acellular pertussis vaccine in school children. Vaccine 1998, Vol. 16: 1604-1610.
52. Mooi-FR; Van Oirschot-H; Heuvelman-K, Van der Heide-HGJ; Gaastra-W; Willems-RJL. Polymorphism in the *Bordetella pertussis* Virulence Factors P.69/Pertactin and

Pertussis Toxin in The Netherlands: Temporal Trends and Evidence for Vaccine-Driven Evolution. Infect. Immun., 1998, Vol. 66: 670-675.
53. Mortimer-EA. Pertussis vaccine in Vaccines (2nd edition, Plotkin-SA and Mortimer-EA. eds.), 1994: 91-135.
54. Nagel-J; Poot-Scholten-EJ. Serum IgA antibody to Bordetella pertussis as an indicator of infection. J. Med. Microbiol., 1983, Vol. 16: 417-426.
55. Nagel-J; de Graaf-S; Schijf-Evers-D. Improved serodiagnosis of whooping cough caused by Bordetella pertussis by determination of IgG anti-LPF antibody levels. Develop. Biol. Standard., 1985, Vol. 61: 325-330.
56. Olin-P; Rasmussen-F; Gustafsson-L; et al. Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Lancet, 1997, Vol. 350: 1569-1577.
57. Oostvogel-PM, van der Avoort-HGAM, Mulders-MN, Rümke-HC, van Steenis-G, van Loon-AM; Virologische en serologische aspecten van de Nederlandse polio-epidemie in 1992 (in Dutch). Ned Tijdschr Geneeskunde, 1993, Vol. 37: 1404-1406.
58. Oostvogel-PM, van Wijngaarden-JK, van der Avoort-HGAM, Mulders-MN, Conyn-van Spaendonck-MAE, Rümke-HC, van Steenis-G, Van Loon-AM; Poliomyelitis outbreak in an unvaccinated community in the Netherlands, 1992-93. Lancet, 1994, Vol. 344: 665-670.
59. Pasetti-M; Eriksson-P; Ferrero-F; Manghi-M. Serum antibodies to diphtheria-tetanus-pertussis vaccine components in Argentine children. Infection, 1997, Vol. 25: 339-345.
60. Pertussis: a critical appraisal. Health Council of the Netherlands: Standing Committee on Infectious Diseases and Immunology, 1997/16.
61. Pichichero-ME; Deloria-MA; Rennels-MB; Anderson-EL; Edwards-KM; Decker-MD; Englund-JA; Steinhoff-MC; Deforest-A; Meade-BD. A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month-old children. Pediatrics 1997, Vol. 100: 772-788.
62. Plotkin-SA; Cadoz-M. The acellular pertussis vaccine trials: an interpretation. Pediatr. Infect. Dis. J., 1997, Vol. 16: 508-517.
63. Podda-A; Bona-G; Canciani-G; Casadei Pistilli-AM; Contu-B; Furlan-R; Meloni-T; Stramare-D; Titone-L; Rappuoli-R; Granoff-DM. Effect of priming with diphtheria and tetanus toxoids combined with whole-cell pertussis vaccine or with acellular pertussis vaccine on the safety and immunogenicity of a booster dose of an acellular pertussis vaccine containing a genetically inactivated pertussis toxin in fifteen- to twenty-one-month-old children. J. Pediatr., 1995, Vol 127: 238-243
64. Pollock-TM; Miller-E; Mortimer-JY; Smith-G. Symptoms after primary immunisation with DTP and with DT vaccine. Lancet, 1984, Vol. 2: 146.
65. Ramsay-MEB; Corbel-MJ; Redhead-K; Ashworth-LAE; Begg-NT. Persistence of antibody after accelerated immunisation with diphtheria/tetanus/pertussis vaccine. B. M. J., 1991, Vol. 302: 1489-1491.
66. Relyveld-E; Oato-NH; Guerin-N; Coursaget-P; Huet-M; Gupta-RK; Determination of circulatin antibodies directed to pertussis toxin and of agglutinogens in children vaccinated with either the whole cell or component pertussis vaccine in France, Japan and Senegal. Vaccine, 1991, Vol. 9: 843-50.
67. Roberts-M; Cropley-I; Chatfield-S; Dougan-G. Protection of mice against respiratory *Bordetella pertussis* infection by intranasal immunization with P.69 and FHA. Vaccine, 1993, Vol. 11: 866-872.
68. Robertson-SE. The immunological basis for immunisation. Poliomyelitis. World Health Organization Geneva 1993, WHO/EPI/GEN/93.16.

69. Robertson-SE, Traverso-HP, Drucker-J, Rovira-EZ, Fabre-Teste-B, Sow-A, N'Diaye-M, Sy-MTA, Diouf-FF; Clinical efficacy of a new enhanced-potency, inactivated poliovirus vaccine. Lancet, 1988, Vol. 1: 897-899.
70. Rümke-HC, Labadie-J, Berbers-GAM, Elzinga-Gholizadea-N, Mensinga-TjT; Immunogenicity of IPV-Vero vaccine. Serological data from a phase I-II clinical study. RIVM report 124001.002, Bilthoven, 1995.
71. Rümke-HC, Oostvogel-PM, van der Veer-M, van Steenis-G, van Loon-AM; Poliomyelitis in Nederland, 1979-1991. Immuniteit en blootstelling. Ned. Tijdschr. Geneeskd., 1993, Vol. 137: 1380-86.
72. Rümke-HC; Oostvogel-PM; van Steenis-G; van Loon-AM. Poliomyelitis in the Netherlands: a review of population immunity and exposure between the epidemics in 1978 and 1992. Epidemiol. Infect., 1995, Vol. 115: 289-298.
73. Rümke-HC; Vaccination against polio. Inactivated polio vaccine used in The Netherlands and Burkina Faso. Trop. Geograph. Med., 1993, Vol. 45: 202-205.
74. Salk-J; Cohen-H, Fillastre-C; Stoeckel-P; Rey-JL; Schlumberger-M; Nicholas-DD; Van Steenis-G; Van Wezel-AL; Triau-R; Saliou-P; Barry-LF; Moreau-JP; Merieux-C. Killed poliovirus antigen titrations in humans. Dev. Biol. Standard., 1978, Vol. 41: 119-132.
75. Salk-J; Stoeckel-P; van Wezel-AL; Lapinleimu-K; van Steenis-G. Antigen content of inactivated poliovirus vaccine for use in a one or two dose regimen. Ann. Clin. Res., 1982, Vol. 14: 204-212.
76. Salmaso-S; Mastrantonio-P; Wassilak-SGF; Giuliano-M; Anemona-A; Giammanco-A; Tozzi-AE; Ciofi degli Atti-ML; Greco-D. Persistence of protection through 33 months of age provided by immunization in infancy with two three-component acellular pertussis vaccines. Vaccine, 1998, Vol. 16: 1270-1275.
77. Schwoebel-V; Dauvisis-A-V; Helynck-B; Gomes-E; Drejer-GF; Schlumberger-M; Bibane-L; Rümke-HC. Community-based evaluation survey of immunizations in Burkina Faso. Bull. WHO, 1992, Vol. 70: 583-590.
78. Stoeckel-P; Schlumberger-M; Parent-G; Maire-B; Van Wezel-AL; Van Steenis-G; Salk-D. Use of killed poliovirus vaccine in a routine immunization program in West Africa. Rev. Infect. Dis., 1984, Vol. 6: S463-6.
79. Storsaeter-J; Hallander-HO; Gustafsson-L; Olin-P. Levels of anti-pertussis antibodies related to protection after household exposure to *Bordetella pertussis*. Vaccine, 1998, Vol. 16: 1907-1916.
80. Sundermann-LC; Korting-van Dören-ILJ; Berbers-GAM; Rümke-HC. Antistofrespons bij kinderen in het Rijksvaccinatie programma, een longitudinaal onderzoek. RIVM rapport 104000001, Bilthoven, 1997.
81. Verschoor-PL; Wilschut-JT; Jonge de-GA; Kostense-J. Frequent symptoms after DTPP vaccinations. Arch. Dis. Child., 1991, Vol. 66: 1408-1412.
82. Wärngård-O; Nilsson-L; Fåhraeus-C; Gustafsson-L; Hallander-HO; Olin-P; Storsaeter-J. Catch-up primary vaccination with acellular pertussis vaccines in 3-4-year-old children, reactogenicity and serological response. Vaccine, 1998, Vol. 16: 480-484.
83. Weiss-A. Mucosal Immune Defenses and the Response of *Bordetella pertussis*. ASM News, 1996, Vol. 63: 22-28.
84. Wirsing von König-CH; Postels-Multani-S; Bogaerts-H; Bock-HL; Laukamp-S; Kiederle-S; Schmitt-HJ. Factors influencing the spread of pertussis in households. Eur. J. Pediatr., 1998, Vol. 157: 391-394.

Declaration of quality control

Undersigned states herewith that the research presented in this report has been carried out according to the OECD principles of Good Clinical Practice (GCP) and that this report reflects a complete, correct and reliable overview of the results obtained.

GCP inspection on study site	20/05/1998
GCP inspection afterwards on data trial laboratory	01/12/1998
GCP checks:	
informed consent verified	100%
check correct in-/exclusion	100%
vaccine accountability monitored	100%
uniformity of assessments trained	100%
handlings recorded on CRF’s	100%
CRF’s monitored	100%
check data trial	100%

Coefficients of variation of the contorl sera in different assays:

PT-ELISA	18.8%
FHA-ELISA	15.7%
PRN-ELISA	18.5%
Diphtheria-ToBI	17.5%
Tetanus-ToBI	15.5%

Quality control officer:

name	:	M.C. Jongerius
laboratory	:	LVO
date	:	09-03-1999
signature	:	

Appendix 1 Mailing list

1-2 Directeur-Generaal Volksgezondheid, Dr. H.J. Schneider
3 Hoofdinspecteur voor de Gezondheidszorg, J. Verhoeff, psychiater
4-5 Inspecteur Infectieziekten van de Inspectie Gezondheidszorg, Drs. J.K. van Wijngaarden, arts
6 Hoofdinspectie voor de preventieve en curatieve gezondheidszorg, mr. H. Plokker
7 Voorzitter van de Gezondheidsraad, Prof. J.J. Sixma
8-9 Landelijke Vereniging voor GGD's
10-75 Artsen infectieziektenbestrijding van de GGD's
76 Landelijk Coördinatiestructuur Infectieziektenbestrijding
77 Werkgroep Rijksvaccinatieprogramma van de Gezondheidsraad, Drs. J. Sekhuis
78 Nationale Vereniging Thuiszorg
79 Nederlandse Vereniging voor Infectieziekten, Prof. Dr. J.W.M. van der Meer
80 Nederlandse Vereniging voor Medische Microbiologie, Prof. Dr. H. Verbrugh
81-95 Stichting Thuiszorg Oost-Veluwe, Drs. D.J.A. Bolscher
96-97 Stichting Provinciale Entadministratie Gelderland, Drs. C. Verhaaff
98-100 Smithkline Beecham
101-103 Wyeth/Lederle Vaccines, Norbert Ahlers
104-106 Pasteur Merieux
107-108 Klinik für Kinder und Jugendliche der Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Prof. Stehr, Dr. I. Bartels
109 Department of Infectious Disease Epidemiologie, Helsinki, Prof. J. Eskola
110 Instituto Superiore di Sanita, Section of Infectious Diseases, Lab. of Epidemiology and Biostatistics, Rome, Dr. S. Salsamo
112 Swedish Institute for Infectious Disease Control, Stockholm, Dr. P. Olin
113 Public Health Laboratory Service, Communicable Disease Centre, London, Dr. E. Miller
114 Department of Health, London, Dr. D. Salisbury
115 Food and Drug Administration, Center for Biologics Evaluation and Research, Dr. B. Meade
116 Prof. Dr. J. Huisman
117 Prof. Dr. J. van der Noordaa
118 Dr. H. Bijkerk
119 Dr. H. Cohen
120 Prof. Dr. R. de Groot
121 Depot Nederlandse Publikaties en Nederlandse Bibliografie
122 Directeur-Generaal RIVM, Ir.Drs. R. van Noort
123 Directeur Volksgezondheid RIVM, Dr. G. Elzinga
124-126 Prof. Dr. B. van der Zeijst, Directeur Sector Vaccins
127-130 Sector Directeur(en)
131 Dr. H. van de Donk.
132 Dr. E.C. Beuvery,
133 Dr. L. van Alphen
134 Drs. L. van Huizen
135 Dr. J.G. Kreeftenberg
136 Dr. H.C. Rümke
137 Dr. M.M. Krasselt
138 Mw. Drs. N. Elzinga-Gholizadea

139 Dr. M.J.W. Sprenger
140 Mw. Dr. M.A.E. Conijn-van Spaendonck
141 Mw. Drs.H. de Melker
142 Dr. J.G. Loeber
143 Dr. J.F.P. Schellekens
144 L.H. Elvers
145 Dr. T.G.Kimman
146 Dr. F.R. Mooi
147 Dr. N. Nagelkerke
148-153 Auteurs
154-162 medewerkers LVO
163 SBD/Voorlichting & Public Relations
164 Bureau Rapportenregistratie
165 Bibliotheek RIVM
166-175 Bureau Rapportenbeheer
175-200 Reserve exemplaren

Appendix 2

Table 7. Geometric mean titers with 95% confidence intervals

Pertussis toxin antibodies

study group	pre-imm.	[95%CI]	post-imm.	[95%CI]
DT-IPV	1.94	[1.16 - 3.25]	2.53	[1.43 - 4.45]
DTP-IPV	1.80	[1.17 - 2.76]	6.55	[3.09 - 13.88]
DT-IPVv	1.41	[1.05 - 1.89]	1.38	[1.04 - 1.84]
DTP-IPVv	1.55	[1.16 - 2.07]	8.14	[3.40 - 19.51]
ACV-SB + DT-IPV	1.99	[1.45 - 2.73]	56.09	[32.11 - 97.95]
ACV-SB + DT-IPVv	2.35	[1.21 - 4.56]	76.77	[41.77 - 141.10]
ACV-WL + DT-IPV	1.95	[1.39 - 2.74]	91.24	[44.88 - 185.49]
ACV-PM + DT-IPV	1.86	[1.24 - 2.78]	91.23	[67.96 - 122.46]

Filamentous Hemagglutin antibodies

study group	pre-imm.	[95%CI]	post-imm.	[95%CI]
DT-IPV	8.60	[4.74 - 15.61]	9.12	[4.88 - 17.04]
DTP-IPV	6.04	[3.92 - 9.32]	38.31	[26.83 - 54.68]
DT-IPVv	4.40	[2.65 - 7.29]	3.88	[2.34 - 6.44]
DTP-IPVv	5.97	[3.86 - 9.24]	31.56	[19.53 - 51.00]
ACV-SB + DT-IPV	7.44	[4.21 - 13.15]	212.41	[130.16 - 346.58]
ACV-SB + DT-IPVv	8.53	[4.96 - 14.67]	268.94	[144.00 - 502.30]
ACV-WL + DT-IPV	5.58	[4.06 - 7.68]	271.21	[199.74 - 368.26]
ACV-PM + DT-IPV	7.84	[5.20 - 11.82]	171.78	[124.08 - 237.82]

Pertactin antibodies

study group	pre-imm.	[95%CI]	post-imm.	[95%CI]
DT-IPV	7.89	[5.09 - 12.23]	7.56	[4.79 11.92]
DTP-IPV	6.22	[4.65 - 8.33]	31.88	[19.74 - 51.48]
DT-IPVv	5.70	[3.93 - 8.28]	6.01	[4.07 - 8.88]
DTP-IPVv	6.56	[4.25 - 10.12]	31.22	[20.22 - 48.20]
ACV-SB + DT-IPV	6.02	[4.49 - 8.07]	146.26	[96.34 - 222.07]
ACV-SB + DT-IPVv	8.84	[6.14 - 12.72]	140.34	[94.71 - 207.97]
ACV-WL + DT-IPV	5.79	[4.22 - 7.94]	71.82	[46.25 - 111.53]
ACV-PM + DT-IPV	6.06	[4.39 - 8.38]	7.85	[5.67 - 10.86]

Table 7 . Geometric mean titers with 95% confidence intervals (continued)

Agglutinating antibodies

study group	pre-imm.	[95%CI]	post-imm.	[95%CI]
DT-IPV	22.29	[11.77 - 42.19]	31.05	[16.44 - 58.63]
DTP-IPV	14.02	[7.48 - 26.27]	133.71	[73.00 - 244.91]
DT-IPVv	14.56	[8.95 - 23.67]	12.29	[7.08 - 21.31]
DTP-IPVv	14.62	[8.68 - 24.62]	133.45	[71.40 - 249.39]
ACV-SB + DT-IPV	17.59	[10.17 - 30.40]	16.51	[10.04 - 27.15]
ACV-SB + DT-IPVv	41.67	[21.92 - 79.23]	43.07	[24.59 - 75.44]
ACV-WL + DT-IPV	8.76	[5.41 - 14.16]	57.00	[24.89 - 130.54]
ACV-PM + DT-IPV	12.57	[7.28 - 21.72]	32.98	[19.86 - 54.76]

IgA antibodies

study group	pre-imm.	[95%CI]	post-imm.	[95%CI]
DT-IPV	1.95	[1.30 - 2.94]	2.16	[1.39 - 3.35]
DTP-IPV	1.44	[1.09 - 1.90]	7.99	[5.44 - 11.72]
DT-IPVv	1.50	[1.12 - 2.02]	1.51	[1.14 - 2.00]
DTP-IPVv	1.57	[1.26 - 1.95]	9.02	[5.82 - 13.98]
ACV-SB + DT-IPV	1.37	[1.08 - 1.73]	1.47	[1.14 - 1.89]
ACV-SB + DT-IPVv	2.40	[1.47 - 3.92]	2.55	[1.60 - 4.05]
ACV-WL + DT-IPV	1.67	[1.16 - 2.40]	2.18	[1.47 - 3.24]
ACV-PM + DT-IPV	1.25	[1.02 - 1.53]	1.60	[1.25 - 2.05]

Fimbriae antibodies

study group	pre-imm.	[95%CI]	post-imm.	[95%CI]
DT-IPV	2.51	[1.30 - 4.86]	2.60	[1.35 - 5.02]
DTP-IPV	1.44	[0.93 - 2.25]	16.37	[8.79 - 30.46]
DT-IPVv	1.57	[1.05 - 2.34]	1.25	[0.88 - 1.77]
DTP-IPVv	1.58	[1.00 - 2.50]	14.19	[8.09 - 24.89]
ACV-SB + DT-IPV	1.80	[1.19 - 2.72]	2.36	[1.50 - 3.70]
ACV-SB + DT-IPVv	3.70	[2.04 - 6.71]	4.69	[2.67 - 8.24]
ACV-WL + DT-IPV	1.16	[0.77 - 1.75]	8.86	[4.20 - 18.70]
ACV-PM + DT-IPV	1.14	[0.74 - 1.77]	3.12	[1.92 - 5.06]

Table 7 Geometric mean titers with 95% confidence intervals (continued)

Diphtheria antibodies

study group	pre-imm.	[95%CI]	post-imm.	[95%CI]
DT-IPV	0.15	[0.07 - 0.30]	2.61	[1.75 - 3.90]
DTP-IPV	0.14	[0.08 - 0.25]	8.45	[5.57 - 12.80]
DT-IPVv	0.12	[0.08 - 0.19]	2.87	[1.54 - 5.37]
DTP-IPVv	0.14	[0.09 - 0.22]	6.57	[3.01 - 14.34]
ACV-SB + DT-IPV	0.15	[0.09 - 0.25]	2.45	[1.51 - 3.96]
ACV-SB + DT-IPVv	0.15	[0.10 - 0.25]	3.65	[2.25 - 5.92]
ACV-WL + DT-IPV	0.10	[0.06 - 0.14]	2.56	[1.73 - 3.77]
ACV-PM + DT-IPV	0.12	[0.07 - 0.19]	2.56	[1.75 - 3.73]

Tetanus antibodies

study group	pre-imm.	[95%CI]	post-imm.	[95%CI]
DT-IPV	0.25	[0.13 - 0.46]	8.61	[5.43 - 13.65]
DTP-IPV	0.27	[0.17 - 0.44]	8.89	[6.04 - 13.08]
DT-IPVv	0.22	[0.14 - 0.34]	7.61	[4.19 - 13.80]
DTP-IPVv	0.27	[0.17 - 0.45]	7.22	[3.91 - 13.32]
ACV-SB + DT-IPV	0.29	[0.16 - 0.53]	8.34	[5.14 - 13.51]
ACV-SB + DT-IPVv	0.38	[0.21 - 0.71]	8.99	[6.68 - 12.10]
ACV-WL + DT-IPV	0.26	[0.17 - 0.40]	9.19	[6.77 - 12.47]
ACV-PM + DT-IPV	0.23	[0.15 - 0.37]	7.81	[5.02 - 12.15]

Table 7. Geometric mean titers with 95% confidence intervals (^{2}log) (continued)

Polio virus type 1 antibodies

study group	pre-imm.	[95%CI]	post-imm.	[95%CI]
DT-IPV	9.26	[8.10 - 10.42]	14.30	[13.29 - 15.32]
DTP-IPV	9.52	[8.39 - 10.65]	13.90	[12.91 - 14.90]
DT-IPVv	8.38	[7.48 - 9.29]	14.00	[13.11 - 14.88]
DTP-IPVv	10.09	[9.26 - 10.92]	14.68	[13.69 - 15.67]
ACV-SB + DT-IPV	9.82	[9.28 - 10.36]	14.68	[13.70 - 15.66]
ACV-SB + DT-IPVv	9.95	[8.43 - 11.47]	14.05	[12.83 - 15.26]
ACV-WL + DT-IPV	9.18	[7.89 - 10.48]	14.27	[12.97 - 15.58]
ACV-PM + DT-IPV	9.17	[7.98 - 10.37]	14.26	[13.34 - 15.18]

Polio virus type 2 antibodies

study group	pre-imm.	[95%CI]	post-imm.	[95%CI]
DT-IPV	8.13	[7.03 - 9.23]	15.22	[14.17 - 16.27]
DTP-IPV	8.52	[7.21 - 9.84]	15.33	[14.25 - 16.41]
DT-IPVv	7.52	[6.80 - 8.25]	15.29	[14.07 - 16.50]
DTP-IPVv	9.18	[8.42 - 9.94]	16.27	[15.18 - 17.36]
ACV-SB + DT-IPV	9.32	[8.23 - 10.41]	15.95	[14.97 - 16.94]
ACV-SB + DT-IPVv	9.05	[7.88 - 10.21]	15.71	[14.73 - 16.70]
ACV-WL + DT-IPV	8.95	[8.09 - 9.81]	14.86	[13.84 - 15.89]
ACV-PM + DT-IPV	7.74	[6.75 - 8.73]	14.78	[13.76 - 15.81]

Polio virus type 3 antibodies

study group	pre-imm.	[95%CI]	post-imm.	[95%CI]
DT-IPV	6.83	[5.55 - 8.10]	13.57	[12.32 - 14.81]
DTP-IPV	7.38	[6.01 - 8.75]	12.81	[11.85 - 13.77]
DT-IPVv	5.95	[5.06 - 6.85]	14.24	[12.94 - 15.54]
DTP-IPVv	6.64	[5.41 - 7.86]	15.82	[14.74 - 16.90]
ACV-SB + DT-IPV	7.64	[6.61 - 8.67]	14.73	[13.84 - 15.62]
ACV-SB + DT-IPVv	7.62	[6.24 - 9.00]	14.62	[13.56 - 15.68]
ACV-WL + DT-IPV	6.86	[5.56 - 8.17]	13.64	[12.50 - 14.77]
ACV-PM + DT-IPV	5.57	[4.87 - 6.27]	14.22	[13.17 - 15.26]

Appendix 3

Table 8A. Systemic adverse events after vaccination

Symptom	Study group	day 1		day 2-3	
		N	(%)	N	(%)
fever (>=38.5 ℃)	DT-IPV	1	(4.3)	1	(4.3)
	DTP-IPV	8	(38.1)	1	(4.8)
	DT-IPVv	0		1	(4.8)
	DTP-IPVv	10	(43.5)	4	(17.4)
	ACV-SB + DT-IPV	0		0	
	ACV-SB + DT-IPVv	2	(9.5)	0	
	ACV-WL + DT-IPV	0		1	(4.3)
	ACV-PM + DT-IPV	0		0	
headache	DT-IPV	0		1	(4.3)
	DTP-IPV	1	(4.8)	3	(14.3)
	DT-IPVv	0		0	
	DTP-IPVv	6	(26.1)	2	(8.7)
	ACV-SB + DT-IPV	1	(4.3)	2	(8.7)
	ACV-SB + DT-IPVv	1	(5.0)	1	(4.8)
	ACV-WL + DT-IPV	0		1	(4.3)
	ACV-PM + DT-IPV	2	(8.3)	0	
listlessness	DT-IPV	3	(13.0)	3	(13.0)
	DTP-IPV	16	(76.2)	11	(52.4)
	DT-IPVv	5	(22.7)	3	(14.3)
	DTP-IPVv	19	(82.6)	9	(39.1)
	ACV-SB + DT-IPV	4	(17.4)	1	(4.3)
	ACV-SB + DT-IPVv	4	(19.0)	2	(9.5)
	ACV-WL + DT-IPV	6	(26.1)	5	(21.7)
	ACV-PM + DT-IPV	6	(25.0)	3	(12.5)
crying	DT-IPV	0		0	
	DTP-IPV	13	(61.9)	4	(19.0)
	DT-IPVv	2	(9.1)	2	(9.5)
	DTP-IPVv	18	(78.3)	4	(17.4)
	ACV-SB + DT-IPV	1	(4.3)	2	(8.7)
	ACV-SB + DT-IPVv	2	(9.5)	0	
	ACV-WL + DT-IPV	3	(13.0)	1	(4.3)
	ACV-PM + DT-IPV	2	(8.3)	0	
Loss of apetite	DT-IPV	0		4	(17.4)
	DTP-IPV	14	(66.7)	2	(9.5)
	DT-IPVv	3	(13.6)	2	(9.5)
	DTP-IPVv	14	(60.9)	8	(34.8)
	ACV-SB + DT-IPV	1	(4.3)	2	(8.7)
	ACV-SB + DT-IPVv	2	(9.5)	2	(9.5)
	ACV-WL + DT-IPV	3	(13.0)	1	(4.3)
	ACV-PM + DT-IPV	2	(8.3)	1	(4.2)

Table 8A. Systemic adverse events after vaccination (continued)

Symptom	study group	day 1		day 2-3	
		N	(%)	N	(%)
nausea	DT-IPV	0		1	(4.3)
	DTP-IPV	2	(9.5)	1	(4.8)
	DT-IPVv	0		0	
	DTP-IPVv	1	(4.3)	0	
	ACV-SB + DT-IPV	0		0	
	ACV-SB + DT-IPVv	0		0	
	ACV-WL + DT-IPV	0		0	
	ACV-PM + DT-IPV	0		0	
skin manifestations	DT-IPV	2	(8.7)	1	(4.3)
	DTP-IPV	2	(9.5)	1	(4.8)
	DT-IPVv	0		2	(9.5)
	DTP-IPVv	1	(4.3)	0	
	ACV-SB + DT-IPV	0		0	
	ACV-SB + DT-IPVv	0		0	
	ACV-WL + DT-IPV	0		1	(4.3)
	ACV-PM + DT-IPV	0		0	

Table 8B. Local adverse events after vaccination

Symptom	Study group	day 1						day 2-3					
		<2.5cm		2.5-5cm		>5cm		<2.5cm		2.5-5cm		>5cm	
		N	%	N	%	N	%	N	%	N	%	N	%
redness left arm	DT-IPV	0		0		0		0		0		0	
	DTP-IPV	3	14.3	6	28.6	4	19.0	1	4.8	5	23.8	5	23.8
	DT-IPVv	0		1	4.5	0		0		0		0	
	DTP-IPVv	2	8.7	6	26.1	8	34.8	4	17.4	3	13.0	8	34.8
	ACV-SB + DT-IPV	1	4.3	0		0		1	4.3	0		0	
	ACV-SB + DT-IPVv	1	4.8	0		0		2	9.5	0		0	
	ACV-WL + DT-IPV	1	4.3	1	4.3	0		1	4.3	0		0	
	ACV-PM + DT-IPV	0		0		0		1	4.2	0		0	
redness right arm	DT-IPV	-		-		-		-		-		-	
	DTP-IPV	-		-		-		-		-		-	
	DT-IPVv	-		-		-		-		-		-	
	DTP-IPVv	-		-		-		-		-		-	
	ACV-SB + DT-IPV	1	4.3	0		0		1	4.3	0		0	
	ACV-SB + DT-IPVv	0		0		0		1	4.8	0		0	
	ACV-WL + DT-IPV	0		0		0		0		0		0	
	ACV-PM + DT-IPV	0		0		0		0		0		0	
swelling left arm	DT-IPV	0		0		0		0		0		0	
	DTP-IPV	1	4.8	2	9.5	2	9.5	0		3	14.3	1	4.8
	DT-IPVv	2	9.1	0		0		0		0		0	
	DTP-IPVv	2	8.7	5	21.7	2	8.7	2	8.7	2	8.7	3	13.0
	ACV-SB + DT-IPV	0		1	4.3	0		1	4.3	0		0	
	ACV-SB + DT-IPVv	0		0		0		0		0		0	
	ACV-WL + DT-IPV	0		0		0		1	4.3	0		0	
	ACV-PM + DT-IPV	1	4.2	0		0		1	4.2	0		0	
swelling right arm	DT-IPV	-		-		-		-		-		-	
	DTP-IPV	-		-		-		-		-		-	
	DT-IPVv	-		-		-		-		-		-	
	DTP-IPVv	-		-		-		-		-		-	
	ACV-SB + DT-IPV	0		0		0		1	4.3	0		0	
	ACV-SB + DT-IPVv	1	4.8	0		0		0		0		0	
	ACV-WL + DT-IPV	1	4.3	0		0		0		0		0	
	ACV-PM + DT-IPV	1	4.2	0		0		0		0		0	

Table 8B. Local adverse events after vaccination (continued)

Symptom	Study group	day 1		day 2-3	
		N	(%)	N	(%)
itching left arm	DT-IPV	0		0	
	DTP-IPV	0		1	(4.8)
	DT-IPVv	0		0	
	DTP-IPVv	2	(9.1)	0	
	ACV-SB + DT-IPV	0		0	
	ACV-SB + DT-IPVv	0		0	
	ACV-WL + DT-IPV	0		0	
	ACV-PM + DT-IPV	0		0	
itching right arm	DT-IPV	-		-	
	DTP-IPV	-		-	
	DT-IPVv	-		-	
	DTP-IPVv	-		-	
	ACV-SB + DT-IPV	0		0	
	ACV-SB + DT-IPVv	0		0	
	ACV-WL + DT-IPV	0		0	
	ACV-PM + DT-IPV	1	(4.2)	0	
pain at vaccination site left arm	DT-IPV	5	(21.7)	0	
	DTP-IPV	19	(90.5)	15	(71.4)
	DT-IPVv	8	(36.4)	1	(4.8)
	DTP-IPVv	20	(87.0)	14	(60.9)
	ACV-SB + DT-IPV	6	(26.1)	2	(8.7)
	ACV-SB + DT-IPVv	6	(28.6)	2	(9.5)
	ACV-WL + DT-IPV	6	(26.1)	3	(13.0)
	ACV-PM + DT-IPV	3	(12.5)	1	(4.2)
pain at vaccination site right arm	DT-IPV	-		-	
	DTP-IPV	-		-	
	DT-IPVv	-		-	
	DTP-IPVv	-		-	
	ACV-SB + DT-IPV	3	(13.0)	1	(4.3)
	ACV-SB + DT-IPVv	4	(19.0)	1	(4.8)
	ACV-WL + DT-IPV	4	(17.4)	0	
	ACV-PM + DT-IPV	4	(16.7)	0	
not using arm left arm	DT-IPV	2	(8.7)	0	
	DTP-IPV	15	(71.4)	10	(47.6)
	DT-IPVv	4	(18.2)	0	
	DTP-IPVv	17	(73.9)	11	(47.8)
	ACV-SB + DT-IPV	3	(13.6)	1	(4.5)
	ACV-SB + DT-IPVv	1	(4.8)	0	
	ACV-WL + DT-IPV	3	(13.0)	1	(4.3)
	ACV-PM + DT-IPV	1	(4.2)	1	(4.2)
not using arm right arm	DT-IPV	-		-	
	DTP-IPV	-		-	
	DT-IPVv	-		-	
	DTP-IPVv	-		-	
	ACV-SB + DT-IPV	1	(4.5)	0	
	ACV-SB + DT-IPVv	2	(9.5)	0	
	ACV-WL + DT-IPV	2	(8.7)	0	
	ACV-PM + DT-IPV	2	(8.3)	0	

Appendix 4

To analyse the development of antibody levels, the differences of the ln-transformed post and pre vaccination antibody titers were calculated.
Multiple linear regression models were built with these difference as dependent variables.
Indicator variables were used as independent variables as follows:

	indicator variables:					
study group	WCV	ACV	SB	WL	PM	IPVvero
DT-IPV	0*	0	0	0	0	0
DTP-IPV	1*	0	0	0	0	0
DT-IPVv	0	0	0	0	0	1
DTP-IPVv	1	0	0	0	0	1
ACV-SB	0	1	1	0	0	0
ACV-SBv	0	1	1	0	0	0
ACV-WL	0	1	0	1	0	0
ACV-PM	0	1	0	0	1	0

* 0 = no
1 = yes

The regression coefficient (r.c.) is a measure of the difference in antibody titers between the vaccine groups for the pertussis, diphtheria and tetanus antigens.

For example: $r.c._{FIM} = [\ln(FIMpost) - \ln(FIMpre)]^{wcP+} - [\ln(FIMpost) - \ln(FIMpre)]^{wcP-}$

Subtracting two logarithms amounts to the same thing as taking the logarithm of the quotient, i.c.:

$$r.c._{FIM} = \ln[(FIMpost / FIMpre)]^{wcP+} - \ln[(FIMpost / FIMpre)]^{wcP-}$$

$$r.c._{FIM} = \ln \frac{[(FIMpost) / (FIMpre)^{wcP+}]}{[(FIMpost) / (FIMpre)^{wcP-}]}$$

$$\exp^{r.c\ FIM} = \frac{[(FIMpost) / (FIMpre)^{wcP+}]}{[(FIMpost) / (FIMpre)^{wcP-}]}$$

Because polio titers were expressed as ^{2}log-reciprocal titers the meaning of the regression coefficient is somewhat different:

$$r.c._{POLIO} = [(Ppost) - (Ppre)]^{vero+} - [(Ppost) - (Ppre)]^{vero-}$$

Appendix 5

UTN	sample	group	PT	FHA	PRN	Aggl	FIM	IgA	Diph	Tet	Polio-I	Polio-II	Polio-III
101	1	1	1	1	5	64	5.6	1	0.1	0.4	9	6	8
101	2	1	1	1	5	32	4.7	1	3.6	40.0	13	18	14
111	1	1	1	2	2	8	1.4	1	0.0	0.1	7	5	4
111	2	1	1	2	3	64	1.4	1	1.5	6.5	11	19	17
117	1	1	2	28	34	32	2.8	6	0.2	0.4	17	10	10
117	2	1	1	26	29	64	2.3	4	3.4	11.8	14	14	16
131	1	1	1	4	2	64	9.4	1	0.6	0.4	9	8	6
131	2	1	1	10	3	64	11.4	1	8.8	18.8	17	16	15
136	1	1	1	6	4	4	0.5	4	0.3	0.0	11	10	9
136	2	1	1	8	5	4	0.5	1	2.1	0.7	12	13	15
145	1	1	1	14	8	4	1.3	1	0.0	0.0	6	7	3
145	2	1	1	4	3	4	0.5	1	0.7	0.9	15	14	11
148	1	1	16	4	13	128	24.2	4	10.3	0.2	8	7	8
148	2	1	3	4	9	256	18.6	4	3.0	33.6	14	18	14
156	1	1	3	22	11	32	2.2	2	0.4	1.9	9	11	11
156	2	1	1	27	19	32	1.9	2	6.2	14.7	15	18	18
179	1	1	1	3	3	4	0.5	1	0.0	0.2	10	8	4
179	2	1	1	3	3	4	0.5	1	1.3	2.6	16	17	9
188	1	1	1	3	2	32	1.9	2	0.0	0.3	8	6	5
188	2	1	2	4	4	32	1.8	4	1.0	11.0	16	17	14
192	1	1	1	11	7	4	0.5	1	0.1	1.2	10	6	1
192	2	1	3	8	7	4	0.5	1	1.3	8.1	16	15	5
194	1	1	1	1	1	4	0.5	1	0.0	0.1	5	7	5
194	2	1	100	13	1	128	9.6	10	0.9	3.4	13	11	10
209	1	1	1	22	23	128	16.0	2	0.2	0.5	6	9	8
209	2	1	2	18	18	128	12.0	2	7.1	21.0	14	17	11
217	1	1	2	4	7	32	3.2	1	0.1	0.1	7	4	6
217	2	1	2	1	3	16	2.7	1	0.9	6.2	15	11	14
218	1	1	1	179	92	512	54.7	23	0.3	0.3	11	10	8
218	2	1	10	169	81	512	38.8	30	8.0	9.2	15	16	14
227	1	1	2	18	2	16	0.5	1	0.1	0.1	7	7	4
227	2	1	2	14	1	8	0.5	1	1.5	6.6	15	15	14
230	1	1	1	2	1	4	0.5	1	0.1	0.1	11	5	5
230	2	1	2	1	2	8	0.5	1	3.9	5.5	21	18	16
233	1	1	1	2	1	8	0.5	1	0.0	0.1	7	8	4
233	2	1	3	2	2	32	0.5	1	2.4	7.5	11	16	13
244	1	1	1	19	7	32	3.9	1	0.2	0.5	12	12	9
244	2	1	1	26	7	64	3.3	2	2.6	19.4	11	13	14
258	1	1	1	25	21	4	0.5	3	1.9	2.9	11	9	8
258	2	1	2	41	21	4	0.5	3	14.9	34.7	15	13	15
261	1	1	43	89	49	128	35.6	13	2.0	4.1	13	15	13
261	2	1	46	109	62	128	46.4	17	8.0	14.5	13	14	12
277	1	1	37	25	16	128	7.5	7	0.0	0.1	9	7	7
277	2	1	23	39	25	128	10.8	6	0.5	3.2	11	16	16
280	1	1	7	16	7	32	5.2	1	0.4	1.1	10	10	11
280	2	1	1	14	7	32	4.1	1	5.3	22.1	16	11	15
104	1	2	1	2	7	64	7.5	2	0.6	0.4	9	8	8
104	2	2	1	45	56	512	63.7	21	27.3	19.3	15	14	11
108	1	2	1	30	23	64	4.4	2	0.7	0.2	10	7	10
108	2	2	13	131	64	128	21.6	16	17.1	4.1	12	15	11
125	1	2	6	6	1	2	0.5	1	1.2	10.6	15	16	14
125	2	2	1	13	3	32	5.2	5	5.9	14.6	14	13	14
126	1	2	8	2	4	2	0.5	1	1.2	0.4	9	13	12
126	2	2	10	14	26	32	2.1	5	34.0	19.5	15	17	16

UTN	sample	group	PT	FHA	PRN	Aggl	FIM	IgA	Diph	Tet	Polio-I	Polio-II	Polio-III
134	1	2	5	19	7	4	0.5	1	0.1	0.3	12	11	12
134	2	2	6	33	115	128	5.8	1	12.0	13.7	14	19	14
137	1	2	3	23	7	32	2.9	1	0.1	0.5	8	11	4
137	2	2	52	100	104	256	38.8	5	2.8	10.4	15	17	16
158	1	2	1	7	6	32	2.2	1	0.0	0.0	10	9	10
158	2	2	6	31	7	256	13.6	4	2.1	0.9	11	19	15
159	1	2	26	20	13	64	3.4	5	0.1	0.1	9	8	6
159	2	2	105	79	44	256	26.3	20	3.2	4.0	11	13	11
165	1	2	3	22	16	32	2.6	1	0.1	0.4	9	5	7
165	2	2	25	55	62	2560	186.0	24	11.6	39.3	18	18	15
166	1	2	1	8	1	8	1.4	1	0.2	0.1	10	12	5
166	2	2	3	43	29	128	21.9	11	10.5	3.9	16	17	15
171	1	2	1	2	4	4	0.5	4	0.1	0.1	11	10	9
171	2	2	1	13	46	32	3.2	4	8.8	5.9	13	10	9
175	1	2	1	6	5	64	2.7	1	0.1	0.2	9	8	7
175	2	2	25	28	32	128	26.4	45	3.8	8.0	12	17	14
211	1	2	1	5	5	32	2.5	1	0.1	0.1	10	7	4
211	2	2	61	10	8	256	56.0	6	3.4	3.4	16	18	11
212	1	2	1	3	11	64	4.0	1	0.3	0.5	9	8	9
212	2	2	70	41	31	512	62.9	6	44.7	26.1	11	15	11
222	1	2	1	3	11	16	1.2	7	0.1	0.8	15	6	4
222	2	2	38	16	44	128	23.4	21	4.1	9.1	10	14	11
226	1	2	1	12	1	4	0.5	2	0.1	0.4	9	10	7
226	2	2	1	22	41	64	9.7	6	4.8	17.9	13	15	14
240	1	2	1	2	17	128	6.8	1	0.5	0.2	11	7	8
240	2	2	3	109	333	512	60.8	6	25.9	9.1	13	15	13
243	1	2	1	3	2	4	0.5	1	0.1	0.2	5	6	3
243	2	2	1	49	20	128	17.7	8	12.0	9.2	15	15	11
245	1	2	1	2	1	4	0.5	1	0.1	0.1	8	4	5
245	2	2	3	90	9	128	27.9	8	5.0	10.5	17	16	15
246	1	2	1	14	6	4	0.5	2	0.1	0.3	6	6	5
246	2	2	1	95	27	4	0.5	4	3.5	6.0	16	12	11
262	1	2	4	3	4	4	1.0	1	0.3	0.2	6	7	6
262	2	2	2	36	19	64	6.1	8	21.2	14.0	15	13	11
107	1	3	1	1	3	8	0.5	1	0.1	0.1	11	6	9
107	2	3	1	1	6	8	0.5	1	7.1	14.0	11	17	20
113	1	3	1	5	3	16	0.5	1	0.1	0.1	5	7	3
113	2	3	1	7	3	16	1.4	2	3.0	5.0	16	13	16
119	1	3	1	2	2	32	1.8	1	0.1	0.1	8	9	6
119	2	3	1	1	5	16	1.7	3	1.3	13.7	13	15	15
132	1	3	6	2	1	4	0.5	3	0.1	1.2	10	11	8
132	2	3	4	3	6	4	0.5	3	2.2	17.5	11	17	17
142	1	3	1	26	8	32	5.9	5	0.2	0.3	6	6	5
142	2	3	1	21	6	64	3.5	5	1.3	1.6	14	17	16
150	1	3	1	1	1	4	1.7	1	0.1	0.1	9	7	2
150	2	3	1	1	1	4	1.3	1	1.3	1.8	13	12	11
161	1	3	1	4	9	32	2.2	1	0.1	0.2	9	6	7
161	2	3	1	4	11	32	1.8	1	12.7	6.2	17	21	16
163	1	3	1	2	14	32	2.2	2	0.2	0.1	11	7	7
163	2	3	1	2	5	4	1.0	3	11.7	13.0	14	15	15
167	1	3	1	2	42	8	1.2	1	0.5	0.4	11	8	9
167	2	3	1	4	59	8	1.3	1	0.1	0.2	15	16	15
176	1	3	2	12	4	4	0.5	1	0.0	0.1	10	6	6
176	2	3	1	6	3	4	0.5	1			17	17	16
180	1	3	2	1	2	32	10.6	1	0.1	0.3	8	7	4
180	2	3	1	1	1	64	4.0	1	1.6	28.6	15	17	9
186	1	3	1	17	7	32	1.0	3	0.1	0.4	8	10	6
186	2	3	1	9	5	16	0.5	1	3.8	42.7	16	19	17
203	1	3	1	11	3	8	1.6	1	0.3	0.3	10	8	7

UTN	sample	group	PT	FHA	PRN	Aggl	FIM	IgA	Diph	Tet	Polio-I	Polio-II	Polio-III
203	2	3	1	1	1	32	1.4	1	14.4	29.0	15	16	15
207	1	3	1	17	6	32	3.1	1	0.1	0.6	8	8	7
207	2	3	3	17	9	128	3.7	1	8.5	11.0	11	11	9
214	1	3	4	7	11	64	3.8	1	3.0	2.0	9	6	4
214	2	3	6	10	12	64	3.5	1	48.0	27.0	11	16	14
224	1	3	1	6	14	8	0.5	7	0.0	0.2	5	5	6
224	2	3	1	13	29	8	0.5	4	0.7	3.9	13	13	14
239	1	3	1	1	1	4	1.4	1	0.1	0.1	6	8	4
239	2	3	1	3	1	2	0.5	1	1.8	3.3	15	18	11
242	1	3	1	9	10	128	4.6	1	0.2	0.9	8	7	4
242	2	3											
249	1	3	1	2	1	4	0.5	1	0.1	0.1	11	9	8
249	2	3	1	1	1	4	0.5	1	2.9	4.4	16	12	11
260	1	3	10	2	4	4	2.7	1	0.1	0.1	8	10	8
260	2	3	2	3	2	4	2.1	1	0.9	3.3	13	14	16
269	1	3	1	7	3	64	3.1	2	0.2	0.5	7	6	5
269	2	3	1	5	1	32	2.6	1	2.2	17.0	13	14	11
278	1	3	2	42	29	8	1.1	6	0.1	0.1	6	8	4
278	2	3	6	31	21	4	1.3	5	3.8	15.1	15	11	15
102	1	4	5	9	7	32	2.3	2	0.2	0.6	11	9	5
102	2	4	38	64	16	256	20.3	8	7.4	7.4	13	17	15
114	1	4	4	67	57	32	3.6	4	0.1	0.6	10	14	5
114	2	4											
120	1	4	2	4	1	8	1.0	1	0.0	0.1	9	10	5
120	2	4	1	39	18	128	7.4	3	2.4	8.8	18	19	21
127	1	4	1	5	9	8	0.5	1	0.4	0.7	10	10	10
127	2	4	12	1	45	128	12.4	12	59.3	7.4	15	14	15
133	1	4	1	4	7	8	0.5	3	0.2	0.2	11	12	11
133	2	4	1	40	27	32	3.4	10	5.4	7.4	12	15	16
144	1	4	1	3	3	4	0.5	1	0.1	0.2	11	6	9
144	2	4	1	13	18	128	14.8	41	25.7	22.4	17	20	18
152	1	4	1	3	3	4	0.5	1	0.4	0.4	9	10	4
152	2	4	57	53	40	128	6.9	3	44.0	12.2	13	16	17
154	1	4	1	5	1	32	3.2	1	0.1	0.2	11	11	3
154	2	4	3	61	49	512	17.1	4	0.0	0.1	12	14	15
170	1	4	12	76	107	8	3.0	3	0.1	0.1	10	7	4
170	2	4	209	211	237	64	11.8	6	0.3	1.1	12	14	11
177	1	4	1	3	1	8	1.3	1	0.3	0.8	16	9	7
177	2	4	1	24	12	64	12.8	3	20.0	18.9	18	23	19
178	1	4	1	2	4	32	1.3	1	0.0	0.0	11	8	6
178	2	4	105	49	60	256	20.8	2	4.6	4.9	16	16	17
191	1	4	2	17	11	64	3.9	1	0.2	0.3	9	10	5
191	2	4	95	42	37	256	49.3	33	8.8	9.0	16	18	18
199	1	4	3	18	20	64	4.4	2	0.4	1.6	8	7	4
199	2	4	146	137	90	256	51.7	73	9.4	12.0	17	17	16
200	1	4	1	3	1	4	0.5	2	0.0	0.0	11	8	5
200	2	4	2	6	4	64	2.4	6	2.4	2.6	15	16	16
210	1	4	2	6	6	256	30.9	3	0.3	0.6	10	11	11
210	2	4	36	24	25	1280	104.6	36	6.1	14.9	12	13	15
216	1	4	2	6	10	4	0.5	2	0.7	0.9	10	9	9
216	2	4	7	21	29	256	21.4	5	34.1	14.8	12	13	11
235	1	4	1	2	4	4	0.5	1	0.1	0.2	7	7	8
235	2	4	1	49	24	4	0.5	33	9.8	21.3	16	15	18
236	1	4	1	4	11	64	3.2	1	0.2	0.2	9	7	7
236	2	4	36	21	43	512	51.0	8	22.0	40.1	13	19	17
255	1	4	2	3	6	32	3.2	2	0.2	0.3	11	11	7
255	2	4	42	26	55	512	45.0	5	8.7	4.0	12	15	15
257	1	4	1	16	55	4	2.3	3	0.3	1.5	12	12	12
257	2	4	2	56	217	256	44.4	10	27.3	29.6	14	15	15

UTN	sample	group	PT	FHA	PRN	Aggl	FIM	IgA	Diph	Tet	Polio-I	Polio-II	Polio-III
271	1	4	1	2	2	16	2.3	1	0.3	0.3	9	10	7
271	2	4	1	29	20	128	10.5	7	4.1	8.1	18	15	14
273	1	4	1	4	1	4	0.5	1	0.1	0.1	7	9	5
273	2	4	3	19	5	4	2.3	5	9.3	6.0	16	16	12
276	1	4	1	7	4	32	2.5	3	0.1	0.3	10	9	2
276	2	4	1	64	30	256	37.7	17	3.9	5.5	16	18	17
110	1	5	1	3	13	8	1.0	1	0.1	0.2	10	9	7
110	2	5	24	48	518	16	2.7	1	2.4	6.2	14	18	15
116	1	5	5	1	5	4	2.4	1	0.1	0.2	11	10	10
116	2	5	131	175	82	32	2.3	1	4.4	3.3	13	14	13
121	1	5	7	28	12	16	1.4	2	0.1	0.1	9	10	7
121	2	5	72	200	233	32	3.6	1	5.4	10.0	16	17	13
128	1	5	2	10	12	16	0.5	1	0.1	0.2	11	9	6
128	2	5	16	607	828	32	0.5	2	0.1	0.6	14	18	18
138	1	5	3	12	1	32	3.0	1	0.0	0.1	11	10	7
138	2	5	96	156	38	64	3.1	1	0.5	14.7	13	15	14
151	1	5	1	18	1	2	0.5	1	0.0	0.0	9	5	5
151	2	5	8	60	47	2	0.5	1	1.0	1.6	15	14	16
153	1	5	1	1	1	4	1.6	1	0.1	0.3	9	9	8
153	2	5	342	279	339	8	3.1	2	6.8	17.4	18	17	17
160	1	5	3	136	4	32	2.1	2	0.1	0.2	9	7	7
160	2	5	14	589	110	4	2.3	1	1.9	18.6	18	16	14
169	1	5	1	6	5	32	1.9	1	0.3	1.4	8	9	7
169	2	5	33	125	143	4	1.6	1	6.5	21.1	12	15	14
182	1	5	2	9	4	2	0.5	1	0.1	0.1	9	8	3
182	2	5	69	1293	154	4	0.5	1	2.6	6.4	16	17	11
189	1	5	1	2	2	16	1.3	7	0.4	0.3	11	13	10
189	2	5	83	138	120	8	1.5	1	4.6	5.8	12	15	11
190	1	5	1	11	1	16	1.7	1	0.1	0.2	10	10	8
190	2	5	68	222	349	32	7.0	1	5.2	29.4	15	12	12
202	1	5	1	5	2	64	6.1	2	0.2	0.8	8	5	7
202	2	5	81	66	26	32	8.4	3	4.0	21.7	19	18	15
204	1	5	1	1	2	8	1.1	1	0.3	0.4	10	9	6
204	2	5	94	163	99	16	2.2	1	4.3	4.7	12	13	15
213	1	5	2	4	13	128	4.7	2	0.2	0.5	10	14	7
213	2	5	27	113	64	64	4.5	1	3.9	16.3	12	13	17
232	1	5	3	31	16	64	14.8	3	0.2	0.7	10	11	11
232	2	5	663	2041	357	64	24.2	3	8.1	40.0	14	16	17
241	1	5	5	23	11	128	7.8	1	0.1	0.3	12	15	14
241	2	5	96	172	25	64	8.2	3	1.7	6.3	16	15	14
253	1	5	1	10	15	32	1.9	1	0.3	0.4	11	9	10
253	2	5	11	316	292	32	1.9	2	3.2	4.2	17	16	15
254	1	5	5	30	9	64	5.4	1	0.3	0.5	10	10	8
254	2	5	23	124	200	32	5.2	1	5.6	7.8	16	15	15
267	1	5	4	2	4	4	0.5	1	8.9	10.4	10	8	5
267	2	5	10	23	202	4	0.5	1	0.5	3.5	15	16	14
270	1	5	5	15	5	32	1.1	3	0.1	1.0	7	8	7
270	2	5	722	1074	206	4	1.2	7	1.6	56.2	15	20	18
272	1	5	1	4	14	16	1.3	1	0.1	0.1	11	7	8
272	2	5	73	491	239	32	1.7	3	2.2	3.1	11	21	16
106	1	6	11	3	11	128	9.9	3	0.2	0.8	10	13	14
106	2	6	195	244	148	64	11.6	1	2.8	15.3	14	11	12
109	1	6	1	9	16	64	6.0	1	0.2	0.1	9	9	9
109	2	6	47	217	227	64	7.3	3	3.9	5.6	13	14	12
124	1	6	2	8	1	4	0.5	1	3.1	7.2	6	8	4
124	2	6	30	199	33	4	0.5	1	1.4	5.0	13	16	14
129	1	6	2	167	12	256	40.3	26	0.1	0.7	8	6	7
129	2	6	1065	2232	454	256	21.7	14	14.4	18.1	11	14	13
139	1	6	1	15	10	16	1.1	1	0.2	0.4	8	6	5

UTN	sample	group	PT	FHA	PRN	Aggl	FIM	IgA	Diph	Tet	Polio-I	Polio-II	Polio-III
139	2	6	148	981	305	32	2.9	1	8.1	8.5	16	11	12
140	1	6	1	12	21	64	4.2	3	0.4	0.4	19	9	9
140	2	6	48	1025	278	128	4.9	3	24.7	16.4	10	15	12
141	1	6	1	4	4	4	0.5	1	0.2	1.7	9	7	5
141	2	6	8	107	78	4	0.5	1	5.9	19.3	11	16	15
149	1	6	1	15	9	64	6.9	5	0.3	0.3	12	7	9
149	2	6	110	1553	436	64	8.5	6	11.6	14.8	16	14	19
172	1	6	1	7	11	32	2.5	2	0.3	2.5	10	10	11
172	2	6	170	1332	599	64	7.5	4	5.9	9.3	13	18	17
174	1	6	1	8	14	32	1.5	1	0.0	0.1	7	8	2
174	2	6	49	253	263	64	1.6	1	2.7	4.6	16	18	11
185	1	6	1	5	7	64	3.9	2	0.1	1.0	10	10	10
185	2	6	93	530	114	32	4.3	2	1.5	8.3	16	16	15
193	1	6	1	2	1	32	6.3	1	0.1	0.3	10	8	6
193	2	6	339	229	193	64	13.7	1	1.8	20.5	16	19	16
198	1	6	5	2	5	8	3.4	4	0.1	1.3	9	8	6
198	2	6	130	51	49	32	6.0	4	2.5	12.5	13	17	18
201	1	6	2	7	10	64	4.2	3	0.1	0.2	19	11	8
201	2	6	46	31	77	64	6.0	3	1.3	6.6	15	19	16
221	1	6	1	1	10	64	3.4	1	0.2	0.3	9	7	7
221	2	6	22	61	117	64	6.2	1	7.1	17.0	11	15	16
225	1	6	2	7	1	4	0.5	1	0.1	0.3	11	10	9
225	2	6	16	37	20	4	0.5	1	1.0	9.2	11	15	16
234	1	6	302	33	69	1024	62.1	29	0.1	0.0	9	8	6
234	2	6	1411	430	156	256	45.0	18	6.8	3.4	21	17	16
237	1	6	3	11	6	64	4.5	2	0.3	0.1	8	7	6
237	2	6	89	201	161	64	5.6	3	8.7	7.5	12	16	17
248	1	6	2	4	26	32	2.2	1	0.0	0.1	7	10	5
248	2	6	20	33	92	64	3.6	1	0.3	2.3	17	17	15
250	1	6	1	14	10	32	1.6	2	0.3	1.5	11	17	14
250	2	6	14	300	77	8	1.4	4	7.7	18.3	16	17	14
279	1	6	38	82	3	256	21.5	15	0.1	0.2	8	11	8
279	2	6	109	2148	156	128	21.8	22	1.8	3.5	14	15	11
103	1	7	1	10	5	4	0.5	3	0.1	0.3	9	11	11
103	2	7	4	123	12	4	0.5	3	1.2	6.4	13	11	11
105	1	7	5	6	3	2	0.5	1	0.0	0.0	19	8	12
105	2	7	1943	962	45	2	1.6	2	3.3	4.3	17	18	16
123	1	7	1	6	3	4	0.5	1	0.0	0.1	6	5	7
123	2	7	98	232	56	64	16.6	1	1.9	2.5	16	17	14
130	1	7	1	3	1	4	1.1	1	0.3	0.8	10	6	6
130	2	7											
143	1	7	1	6	4	8	1.1	6	0.1	0.2	11	10	7
143	2	7	114	262	80	32	5.5	5	3.5	9.5	14	16	16
146	1	7	1	9	7	4	0.5	1	0.2	0.2	12	10	10
146	2	7	154	223	70	64	8.3	1	4.8	5.2	11	18	15
157	1	7	1	2	16	32	3.9	2	0.2	0.6	8	9	7
157	2	7	5	168	290	256	24.0	2	4.2	31.5	18	18	17
162	1	7	2	9	7	32	2.2	1	0.1	0.3	12	11	10
162	2	7	182	1611	225	256	85.0	2	4.7	13.3	15	16	15
173	1	7	5	1	3	32	1.9	1	0.1	0.6	7	9	3
173	2	7	862	286	88	2560	212.7	1	3.0	16.0	20	16	12
181	1	7	2	4	1	2	0.5	1	0.1	0.1	6	8	5
181	2	7	78	136	32	2	0.5	1	2.7	3.3	5	14	13
184	1	7	1	9	6	8	0.5	1	0.0	0.1	10	10	8
184	2	7	250	241	139	128	12.7	3	1.2	12.6	15	16	12
196	1	7	1	2	1	8	0.5	1	0.2	0.8	6	10	7
196	2	7	156	310	41	256	56.8	3	5.4	14.8	13	11	9
215	1	7	4	3	11	16	3.2	3	0.2	0.4	9	10	8
215	2	7	136	291	37	256	32.7	6	4.8	13.5	15	11	16

UTN	sample	group	PT	FHA	PRN	Aggl	FIM	IgA	Diph	Tet	Polio-I	Polio-II	Polio-III
219	1	7	5	7	2	16	0.5	1	0.1	0.3	8	7	1
219	2	7	100	154	22	128	12.4	1	4.7	8.6	13	15	11
220	1	7	2	6	6	8	1.3	1	0.1	0.2	9	9	6
220	2	7	23	134	27	128	19.5	1	7.3	13.8	15	16	16
223	1	7	4	3	8	32	3.8	1	0.2	0.3	8	9	8
223	2	7	69	209	71	64	9.8	1	2.0	6.3	15	14	16
229	1	7	1	36	9	4	2.0	3	0.3	1.1	10	7	5
229	2	7	62	500	96	64	11.9	4	6.3	12.4	13	16	13
231	1	7	5	8	1	4	0.5	1	0.0	0.1	5	5	3
231	2	7	396	696	19	16	0.5	1	0.5	4.1	15	13	10
251	1	7	1	5	3	8	3.1	2	0.1	0.2	10	9	7
251	2	7	216	505	73	512	24.5	3	9.8	24.2	12	15	15
252	1	7	1	8	27	32	3.9	3	0.4	0.6	11	13	12
252	2	7	4	210	514	128	16.5	3	2.5	21.8	15	11	15
263	1	7	15	7	25	128	9.8	33	0.1	0.9	9	9	4
263	2	7	496	109	517	64	19.4	41	0.9	14.4	17	16	15
266	1	7	2	5	1	2	0.5	1	0.0	0.2	9	11	4
266	2	7	36	157	95	4	2.0	1	0.5	3.9	15	16	8
268	1	7	2	13	10	4	0.5	2	0.1	0.6	8	7	6
268	2	7	51	341	74	8	1.0	3	0.7	7.3	12	13	15
112	1	8	3	9	13	4	1.1	2	0.2	0.2	8	7	7
112	2	8	100	400	9	64	2.5	6	10.8	6.1	14	16	14
115	1	8	2	12	8	4	0.5	1	0.2	0.3	11	10	9
115	2	8	84	165	6	8	1.8	1	3.3	7.2	13	15	14
118	1	8											
118	2	8											
122	1	8	5	14	6	4	0.5	1	0.5	0.6	6	7	4
122	2	8	44	204	7	4	1.3	1	3.2	10.7	15	14	10
135	1	8	1	26	3	4	0.5	1	0.2	0.5	11	6	6
135	2	8	33	192	5	32	1.8	2	4.9	22.4	13	11	15
147	1	8	1	5	1	2	1.3	1	0.4	0.1	9	7	6
147	2	8	89	242	1	64	9.0	1	5.4	3.6	12	15	16
155	1	8	3	5	9	4	0.5	4	0.0	0.2	11	10	6
155	2	8	75	51	6	4	1.4	3	1.0	5.9	19	12	14
164	1	8	1	3	16	8	0.5	1	0.0	0.1	11	11	4
164	2	8	95	36	23	32	3.1	1	0.8	3.2	13	11	19
168	1	8	1	5	3	2	0.5	1	0.1	0.2	8	7	4
168	2	8	280	153	1	4	0.5	2	7.6	23.2	12	13	14
183	1	8	9	28	6	64	1.2	1	0.1	0.2	10	7	8
183	2	8	65	156	8	64	5.9	1	2.5	9.1	13	17	11
187	1	8	2	9	26	8	0.5	1	0.1	0.5	8	5	4
187	2	8	32	249	41	32	1.7	2	2.4	65.3	16	14	14
195	1	8	1	17	6	32	3.0	2	0.3	0.3	9	9	7
195	2	8	133	414	6	128	15.8	3			16	16	16
197	1	8	1	6	1	32	4.5	1	0.1	0.5	11	10	6
197	2	8	65	122	3	32	6.9	2	4.4	16.8	12	12	14
205	1	8	2	42	49	32	1.6	1	0.0	0.2	5	8	5
205	2	8	78	760	43	64	4.5	1	1.3	30.3	15	14	15
206	1	8	1	11	5	4	0.5	1	0.0	0.1	8	4	6
206	2	8	88	240	8	32	2.3	1	2.9	1.6	14	14	11
208	1	8	1	6	5	128	9.6	1	0.4	0.4	7	7	5
208	2	8	148	136	11	256	30.1	2	3.2	8.7	15	14	14
238	1	8	1	3	4	8	0.5	1	0.2	0.1	18	9	7
238	2	8	55	58	7	16	2.1	1	6.9	10.9	15	14	17
247	1	8	1	1	1	4	0.5	1	0.1	0.2	5	3	2
247	2	8	257	48	6	8	0.5	1	0.8	5.9	15	15	13
256	1	8	1	15	7	32	0.5	1	0.1	0.2	10	11	4
256	2	8	34	225	12	32	0.5	2	0.7	4.2	15	19	16
259	1	8	40	28	8	64	6.3	5	0.1	0.1	8	7	5

UTN	sample	group	PT	FHA	PRN	Aggl	FIM	IgA	Diph	Tet	Polio-I	Polio-II	Polio-III
259	2	8	372	299	10	64	4.8	5	4.0	2.3	13	15	14
264	1	8	1	10	5	32	3.6	1	0.3	0.6	10	11	7
264	2	8	152	191	17	128	17.0	1	2.0	23.7	20	20	12
265	1	8	4	2	1	32	3.3	2	1.5	8.3	11	10	7
265	2	8	161	435	4	64	7.8	3	3.6	10.6	14	19	15
274	1	8	3	7	4	16	0.5	1	0.0	0.1	6	5	4
274	2	8	46	114	3	32	1.7	1	0.4	1.3	13	14	10
275	1	8	1	2	3	64	3.5	1	0.1	0.1	10	7	5
275	2	8	152	167	7	128	6.2	1	3.5	3.2	11	16	19

Legend:

Group 1: DT-IPV
Group 2: DTP-IPV
Group 3: DT-IPVv
Group 4: DTP-IPVv
Group 5: ACV-SB
Group 6: ACV-SBv
Group 7: ACV-WL
Group 8: ACV-PM